University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2014

Role of Pikfyve in Platelet Lysosomal Homeostasis
Sang Hee Min
University of Pennsylvania, claramin76@yahoo.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Cell Biology Commons

Recommended Citation
Min, Sang Hee, "Role of Pikfyve in Platelet Lysosomal Homeostasis" (2014). Publicly Accessible Penn
Dissertations. 1372.
https://repository.upenn.edu/edissertations/1372

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1372
For more information, please contact repository@pobox.upenn.edu.

Role of Pikfyve in Platelet Lysosomal Homeostasis
Abstract
PIKfyve is a lipid kinase that is essential for the synthesis of phosphatidylinositol-3,5-bisphosphate
[PtdIns(3,5)P2], and for the regulation of membrane dynamics within the endolysosomal system in
mammals. Depletion of intracellular pools of PtdIns(3,5)P2 in humans and in mice is associated with
neurodegeneration and early lethality. However, the biological role of PtdIns(3,5)P2 in non-neural tissues
is not well understood. Platelets are hematopoietic cells that function in a variety of physiological
responses. Essential to many of these functions is the activation-dependent release of effectors from
distinct storage granules - alpha granules, dense granules, and lysosomes - that derive from the
endolysosomal system. In this work, we show that platelet-specific ablation of the PIKfyve gene in mice
results in accelerated arterial thrombosis, but also unexpectedly to multiorgan defects that impair
development, body mass, fertility, and survival by inducing inappropriate inflammatory responses
characterized by macrophage accumulation in multiple tissues. Platelet depletion in vivo significantly
impairs the progression of multiorgan defects in these mice, confirming that these defects reflect a
platelet-specific process. Although PIKfyve-null platelets generate and release normal amounts of alpha
granule and dense granule contents, they develop defective maturation and excessive storage of
lysosomal enzymes, which are released upon platelet activation. Remarkably, impairing the secretion of
lysosomes from PIKfyve-deficient platelets in vivo significantly attenuates the multiorgan defects in mice,
suggesting that platelet lysosome secretion contributes to pathogenesis. Together, these results
demonstrate that PIKfyve is an essential regulator for the biogenesis of platelet lysosomes, and highlight
the previously unrecognized and important pathological contributions of platelet lysosomes in
inflammation, arterial thrombosis, and macrophage biology.
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ABSTRACT
ROLE OF PIKFYVE IN PLATELET LYSOSOMAL HOMEOSTASIS
Sang Hee Min
Charles S. Abrams

PIKfyve is a lipid kinase that is essential for the synthesis of phosphatidylinositol-3,5bisphosphate [PtdIns(3,5)P2], and for the regulation of membrane dynamics within the
endolysosomal system in mammals. Depletion of intracellular pools of PtdIns(3,5)P2 in
humans and in mice is associated with neurodegeneration and early lethality. However,
the biological role of PtdIns(3,5)P2 in non-neural tissues is not well understood. Platelets
are hematopoietic cells that function in a variety of physiological responses. Essential to
many of these functions is the activation-dependent release of effectors from distinct
storage granules - alpha granules, dense granules, and lysosomes - that derive from the
endolysosomal system. In this work, we show that platelet-specific ablation of the
PIKfyve gene in mice results in accelerated arterial thrombosis, but also unexpectedly to
multiorgan defects that impair development, body mass, fertility, and survival by
inducing inappropriate inflammatory responses characterized by macrophage
accumulation in multiple tissues. Platelet depletion in vivo significantly impairs the
progression of multiorgan defects in these mice, confirming that these defects reflect a
platelet-specific process. Although PIKfyve-null platelets generate and release normal
amounts of alpha granule and dense granule contents, they develop defective maturation
and excessive storage of lysosomal enzymes, which are released upon platelet activation.
Remarkably, impairing the secretion of lysosomes from PIKfyve-deficient platelets in
vivo significantly attenuates the multiorgan defects in mice, suggesting that platelet
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lysosome secretion contributes to pathogenesis. Together, these results demonstrate that
PIKfyve is an essential regulator for the biogenesis of platelet lysosomes, and highlight
the previously unrecognized and important pathological contributions of platelet
lysosomes in inflammation, arterial thrombosis, and macrophage biology.
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CHAPTER 1: INTRODUCTION 1
1.1) Phosphoinositides: overview
Phosphatidilinositol (PtdIns) is a class of membrane phospholipid, which is
composed of an inositol head group, a glycerol backbone, and two fatty acid tails. PtdIns
is modified by transient phosphorylation of its inositol head group, which generates
various phosphorylated forms of PtdIns, known as phosphoinositides (Hokin and Hokin
1953, Hokin 1996). PtdIns and phosphoinositides are very minor components of the
membrane phospholipids, and yet they are essential in the regulation of diverse cellular
processes, which include membrane trafficking, cytoskeletal dynamics, membrane
transports, and nuclear events in many different cells (Di Paolo and De Camilli 2006).
A total of seven phosphoinositides have been identified that derive from PtdIns
following the reversible phosphorylation of the hydroxyls situated in the D3, D4 and D5
positions of the inositol head group. These seven phosphoinositides are: PtdIns(3)P,
PtdIns(4)P, PtdIns(5)P, PtdIns(3,5)P2, PtdIns(3,4)P2, PtdIns(4,5)P2, and PtdIns(3,4,5)P3
(Figure 1). The turnover of phosphoinositides occurs on the cytosolic leaflet in the
cellular membrane or on the membrane of intracellular organelles by specific
phosphoinositide-metabolizing enzymes, which include lipid kinases, lipid phosphatases,
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  Parts of this chapter have been published as:
Min SH, Abrams CS
Regulation of platelet plug formation by phosphoinositide metabolism.
Blood. 2013 Aug 22;122(8):1358-65.
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and phospholipases (Heck, Mellman et al. 2007, Krauss and Haucke 2007). The
individual phosphoinositide-metabolizing enzymes have distinct expression and
regulation patterns and contribute to the spatiotemporal organization of specific
phosphoinositides (Krauss and Haucke 2007). Consequently, the different
phosphoinositides are rapidly and reversibly generated on the membranes of distinct
cellular compartments.

Figure 1.1. Metabolism of phosphoinositides by phosphoinositide-metabolizing
enzymes. Shown is the relationship between different phosphoinositides and their
metabolizing lipid kinases (red arrows), lipid phosphatases (blue arrows) and
phospholipase C (green arrows).
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Once synthesized, the individual phosphoinositides can be recognized by selective
subsets of proteins containing specific phosphoinositide-binding domains, such as PH
(pleckstrin homology), FYVE (Fab1, YOTB, Vac1, EEA1 homology), PX (phox
homology), PROPPINs (β-propellers that bind phosphoinositides), ENTH (epsin Nterminal homology), and ANTH (AP180 N-terminal homology) (Lemmon 2008). For
example, PtdIns(4,5)P2 on the plasma membrane binds to ENTH domain of Epsin and
indirectly recruit Epsin binding proteins such as AP2 to bind clathrin coats and form
clathrin-coated vesicles. This recruitment of a specific effector protein to a
phosphoinositide confined in a specific cellular compartment provides each of the
individual phosphoinositides with unique functions in cells.
The essential physiological functions of phosphoinositides have been
demonstrated by many human disorders or abnormal phenotypes in mice associated with
mutations in the phosphoinositide-metabolizing enzymes (Nicot and Laporte 2008,
McCrea and De Camilli 2009).

1.2) Phosphoinositide organization during platelet plug formation
Platelet plug formation is essential during hemostasis, but when perturbed, it can
lead to pathological bleeding or thrombosis (Jackson 2011). Thus, this is a tightly
controlled process requiring activation of platelets under carefully modulated intracellular
signaling transduction (Jackson 2007, Stalker, Newman et al. 2012). When there is a
vascular injury, platelets tether to collagen or to von Willebrand factor (vWF) and initiate
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an intracellular signaling cascade that leads to firm and stable adhesion to the
subendothelium (Ruggeri and Mendolicchio 2007). This is followed by integrin
activation on the platelet surface, and subsequently aggregation between platelets
(Jackson 2007). Further stabilization of the platelet plug and prevention of platelet
disaggregation requires additional amplification of the platelet signaling pathways. Over
the past few decades, accumulating evidence indicates that phosphorylated
phosphatidylinositols are crucial components in this complex network of platelet
signaling.

The role of PtdIns(4,5)P2 signaling in platelet biology
PtdIns(4,5)P2 synthesis by PIP5KI
PtdIns(4,5)P2 is a predominant phosphoinositide in the cellular membrane.
PtdIns(4,5)P2 is synthesized either from PtdIns(4)P by the D5-OH kinase activity of
PIP5KI (Hay, Fisette et al. 1995) or from PtdIns(5)P by the D4-OH kinase activity of
phosphatidylinositol 5-phosphate 4-kinase type II (PIP5KII or PIP4K) (Rameh, Tolias et
al. 1997, Clarke, Wang et al. 2010). Studies comparing the relative labeling rate of the
D4- and D5- hydroxyl positions of the inositol ring suggest that the catalytic activity of
the D5 position is more efficient (King, Hawkins et al. 1989, Stephens, Hughes et al.
1991). In addition, the relative abundance of PtdIns(4)P is much greater than PtdIns(5)P
(Stephens, Hughes et al. 1991, Roberts, Clarke et al. 2005), suggesting that PIP5KI
phosphorylation of PtdIns(4)P is the major source of PtdIns(4,5)P2 synthesis. In
agreement with these findings, while the loss of PIP4K does not reduce the synthesis of
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PtdIns(4,5)P2 in mammalian cells, the loss of PIP5KI significantly decreases the
intracellular pool of PtdIns(4,5)P2. This demonstrates that PIP5KI is the predominant
kinase in the generation of PtdIns(4,5)P2.

PIP5KI isoforms and splice variants in platelets
PIP5KI exists in three different isoforms (α, β and γ). Intriguingly, all three
PIP5KI isoforms can synthesize PtdIns(4,5)P2 from PtdIns(4)P (Ishihara, Shibasaki et al.
1996, Loijens and Anderson 1996, Ishihara, Shibasaki et al. 1998). This in turn raises the
question why PIP5KI exists in more than one isoform? Recently, work by our group as
well as by others addressed this question using genetically engineered mice lacking each
isoform of PIP5KI in platelets. Platelets contain all three isoforms of PIP5KI, but the
murine PIP5KI-β and PIP5KI-γ are the most abundant forms (Wang, Chen et al. 2008,
Wang, Litvinov et al. 2008). Platelets lacking PIP5KI-β have defective synthesis of
PtdIns(4,5)P2 as well as defective Ins(1,4,5)P3 formation in the first one minute after
stimulation with thrombin (Wang, Chen et al. 2008). Consequently, these platelets
display defective aggregation ex vivo and impaired formation of an occluding thrombus
in vivo (Wang, Chen et al. 2008). Remarkably, platelets lacking both PIP5KI-α and
PIP5KI-β have a complete loss of Ins(1,4,5)P3 formation, even though they still contain
PIP5KI-γ (Wang, Chen et al. 2008). This suggests that PIP5KI-γ synthesizes a pool of
PtdIns(4,5)P2 that is not required for the synthesis of second messengers such as
Ins(1,4,5)P3.
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As predicted, platelets lacking PIP5KI-γ can still produce normal amounts of
Ins(1,4,5)P3 upon stimulation with thrombin, despite having impaired synthesis of
PtdIns(4,5)P2 (Wang, Litvinov et al. 2008). But in contrast to cells lacking PIP5KI-α or
PIP5KI-β, megakaryocytes or platelets lacking PIP5KI-γ have a significant defect in
anchoring their cell membranes to the underlying cytoskeleton (Wang, Litvinov et al.
2008, Wang, Zhao et al. 2013). This suggests that PIP5KI-γ synthesis of PtdIns(4,5)P2
does not contribute to Ins(1,4,5)P3 formation, but rather directly affects the membrane
anchoring of the cytoskeleton. Additional evidence suggests that PIP5KI-γ synthesizes a
discrete pool of PtdIns(4,5)P2 that interacts directly with actin-binding proteins (such as
talin) (Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002). Once bound to
PtdIns(4,5)P2, these actin-regulating proteins are enabled to anchor the cell membrane to
the underlying cytoskeleton (Gilmore and Burridge 1996).
These studies demonstrate that although all PIP5KI isoforms can synthesize
PtdIns(4,5)P2, they have non-redundant functional roles in platelets. How the different
isoforms of PIP5KI promote unique physiological effects is unclear, but several
mechanisms are proposed. First, although PIP5KI-α and PIP5KI-β have homologous
primary sequences, PIP5KI-γ is structurally different (Loijens and Anderson 1996, Wang,
Chen et al. 2008). This suggests that individual PIP5KI isoforms could be regulated
differently. Second, spatially distinct localization of individual PIP5KI isoforms may
generate discrete pools of PtdIns(4,5)P2. Several studies indicate that different PIP5KI
isoforms are localized in distinct cellular compartments in tissue culture cells. For
instance, PIP5KI-α is more predominant in membrane ruffles (Doughman, Firestone et al.
2003), while PIP5KI-β concentrates close to the endosomes (Padron, Wang et al. 2003),
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and PIP5KI-γ is targeted to focal adhesions and nerve terminals (Wenk, Pellegrini et al.
2001, Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002). In addition, our data
indicate that PIP5KI-α and PIP5KI-β, but not PIP5KI-γ can synthesize the pool of
PtdIns(4,5)P2 utilized by PLC to generate Ins(1,4,5)P3 (Wang, Chen et al. 2008, Wang,
Litvinov et al. 2008). From these studies, one could hypothesize that the pools of
PtdIns(4,5)P2 from different PIP5KI isoforms are highly compartmentalized and targeted
by selective downstream effector molecules, providing unique functions to each of the
PIP5KI isoforms. However, it is also conceivable that only PIP5KI-α and PIP5KI-β can
interact with auxiliary proteins that in turn regulate the activity of downstream effectors
such as PLC. Nevertheless, the exact mechanisms by which different PIP5KI isoforms
fulfill unique niches within platelets need to be further elucidated.
As mentioned above, several groups of researchers have speculated that PIP5KI-γ
might generate PtdIns(4,5)P2 that binds to talin and positions it to participate in signaling
pathways that emanate towards or in response to integrin activation (Gilmore and
Burridge 1996, Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002, Calderwood
and Ginsberg 2003). PIP5KI-γ has two predominant splice variants that differ by the
inclusion of or exclusion of 27 amino acids encoded by the terminal exon of the PIP5K-γ
gene (Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002). These two splice
variants are the longer 90 kDA (p90) splice form and the shorter 87 kDa (p87) splice
form. These additional 27 amino acids allow the p90 splice variant to bind to talin, a
protein that is important for both integrin activation and for linking integrins to the
underlying cytoskeleton (Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002,
Calderwood and Ginsberg 2003). Consequently, platelets and megakaryocytes lacking
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the p90 splice variant of PIP5KI-γ have defective anchoring of their integrins to the
underlying cytoskeleton (Wang, Zhao et al. 2013). This effect depends on the kinase
activity of PIP5KI-γ, which implies that the local synthesis of PtdIns(4,5)P2 by the p90
splice variant plays an important role in maintaining the integrity of the connection
between the cell membrane and actin. Remarkably, platelets lacking this p90 splice
variant of PIP5KI-γ have no obvious defect in the activation of integrins or in cell
adhesion. In contrast, platelets lacking both p87 and p90 PIP5KI-γ do have a defect in
shear-resistant adhesion (Wang, Zhao et al. 2013). These data suggest that although both
the p87 and p90 PIP5KI splice variants can synthesize PtdIns(4,5)P2, they have nonredundant functions in platelet cytoskeletal dynamics and in stable adhesion. This study
further provides evidence that PIP5KI has a variety of intracellular functions. Not only
does PIP5KI produce isolated pools of PtdIns(4,5)P2, it also, because of its individual
isoforms and splice variants, can directly interact and regulate distinct signaling proteins.

Regulation of PIP5KI by small GTPases
Several studies suggest that the localization and kinase activity of PIP5KI
isoforms are regulated by small GTPases of the Rho family. For instance, J. Hartwig and
colleagues demonstrated that thrombin-mediated Rac1 activation induces the synthesis of
PtdIns(4,5)P2 by PIP5KI-α, which in turn leads to actin filament assembly (Hartwig,
Bokoch et al. 1995). The S. Offermanns group showed that exposure of platelets to
thromboxane A2 stimulates Rho and Rho kinase, which thereby activate PIP5KI
(Gratacap, Payrastre et al. 2001). We have shown that PIP5KI is rapidly translocated
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from the cytosol to actin-rich compartments upon platelet activation, but this process is
impaired when the Rho GTPase is inhibited (Chatah and Abrams 2001, Yang, Carpenter
et al. 2004). Together, these works suggest that Rho family GTPases regulate the
trafficking of PIP5KI into the membrane cytoskeleton. Once PIP5KI is positioned next
to its substrate, PtdIns(4)P, PIP5KI is poised to generate PtdIns(4,5)P2.

The role of second messengers Ins(1,4,5)P3 and DAG in platelet biology
Phospholipase C (PLC) hydrolyzes PtdIns(4,5)P2, thereby cleaving the bond
between the glycerol and phosphate moieties to generate the second messengers DAG
and IP3 (Figures 3A) (Eyster 2007). PLCs are classified into six subfamilies based on
sequence homology. They are: PLC-β, PLC-γ, PLC-δ, PLC-ε, PLC-ζ and PLC-η. Many
of these PLC isoforms have multiple variants, leading to a very large and diverse family
of enzymes (Rhee and Choi 1992). Although all PLC isoforms can hydrolyze
PtdIns(4,5)P2 to generate DAG and Ins(1,4,5)P3, each PLC isoform has distinct cellular
expressions, subcellular localizations, and specific modes of activation (Rhee and Bae
1997). This diversity further contributes to the temporo-spatial metabolism of
PtdIns(4,5)P2 signaling.
Ins(1,4,5)P3 is a soluble second messenger that can diffuse through the cytosol
and bind to Ins(1,4,5)P3 receptors (Berridge and Irvine 1989), which in turn function as
Ca2+ channels in the platelet dense tubular systems (DTS). This triggers Ca2+ release from
the DTS to the cytosol, which in turn modifies the cytosolic concentrations of Ca2+, and
regulates diverse downstream signaling effects that include the release of platelet
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secretory granules (Brass and Joseph 1985). In contrast to Ins(1,4,5)P3 generated by
PLC-mediated hydrolysis of PtdIns(4,5)P2, the second messenger DAG simultaneously
generated by this process functions as a signaling molecule that is essential for the
localization and activation of different isoforms of protein kinase C (PKC) (Lapetina,
Reep et al. 1985). In turn, PKC has regulatory functions in many cellular processes,
which include proliferation, apoptosis, survival, and migration (Lapetina, Reep et al.
1985, Griner and Kazanietz 2007). In platelets, DAG-mediated activation of PKC also
leads to the phosphorylation of a 47kDa protein called pleckstrin, which is a protein that
is important in platelet secretion (Lian, Wang et al. 2009).
Human platelets contain PLC-β and PLC-γ. PLC-β has a pleckstrin homology
(PH) domain that binds to the Gβγ subunit of the heterotrimeric G protein on the plasma
membrane. This process activates the catalytic domains of PLC-β. Conversely, after
collagen stimulation, PLC-γ binds to the PtdIns(3,4,5)P3 on the plasma membrane, where
it can be directly phosphorylated by receptor tyrosine kinases (RTK). Upon platelet
activation, all PLC isoforms induce the rapid hydrolysis of PtdIns(4,5)P2 into DAG and
Ins(1,4,5)P3. Patients who have a deficiency of PLC-β, have a mild bleeding disorder
(Lee, Rao et al. 1996, Yang, Sun et al. 1996). Ex vivo, platelets from these patients, or
mice engineered to lack PLC-β isoforms, exhibit abnormal platelet aggregation and
secretion (Lian, Wang et al. 2005). This is due to diminished PLC-β–mediated
Ins(1,4,5)P3 production, intracellular Ca2+ mobilization, and pleckstrin phosphorylation
(Lee, Rao et al. 1996, Yang, Sun et al. 1996, Lian, Wang et al. 2005).
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The role of PtdIns(3,4,5)P3 signaling in platelet functions
PI3K isoforms
Phosphatidylinositol 3-kinases (PI3Ks) can phosphorylate the D3-OH group of
the inositol ring within phosphoinositides to generate PtdIns(3,4,5)P3, PtdIns(3,4)P2, and
PtdIns(3)P (Cantley 2002). There exist three classes of PI3K isoforms (I, II and III)
(Vanhaesebroeck and Waterfield 1999). The class I PI3K are critical for the
phosphorylation of PtdIns(4,5)P2 to generate the second messenger PtdIns(3,4,5)P3 (also
known as PIP3) (Anderson and Jackson 2003). This class of PI3K is subdivided into class
IA (PI3K-α, PI3K-β and PI3K-δ) and IB (PI3K-γ). The class IA PI3K is a heterodimer
that is composed of a catalytic subunit (p110-α, p110-β, and p110-δ) bound to a
regulatory subunit (p85-α, p85-β, p55-γ, p55-α and p50-α) that possesses an SH2 (Src
homology 2) motif. Since SH2 domains bind to tyrosine phosphorylated residues on other
proteins, the regulatory subunit enables class IA PI3K to bind to tyrosine phosphorylated
receptor tyrosine kinases or to adaptor molecules (Gibbins, Briddon et al. 1998). This
process unfolds the PI3K complex, and enables it to phosphorylate PtdIns(4,5)P2 to
generate PtdIns(3,4,5)P3. In contrast, the single member of the class IB PI3K family
(PI3K-γ) is composed of the catalytic subunit p110-γ and the p101 regulatory domain.
This complex becomes enabled to synthesize PtdIns(3,4,5)P3 after p101 binds to the Gβγ
subunit of heterotrimeric G-proteins. However, recent studies suggest that PI3K-β can
also be activated by G protein coupled receptors (GPCRs) (Tang and Downes 1997,
Hazeki, Okada et al. 1998, Kubo, Hazeki et al. 2005) (Guillermet-Guibert, Bjorklof et al.
2008). Regardless of the mechanism, activation of all Type I PI3Ks lead to the synthesis
of PtdIns(3,4,5)P3, which in turn can bind to and activate many downstream effector
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molecules, including the protein kinase, Akt. In addition to class I PI3K isoforms that
synthesize PtdIns(3,4,5)P3, there are class II PI3Ks that phosphorylate PtdIns(4)P to
synthesize PtdIns(3,4)P2, and there are class III PI3Ks that phosphorylate the D-3
position of PtdIns to form PtdIns(3)P. While the role of class I PI3K in platelet adhesion
by activation of αIIbβ3 has been extensively studied (Jackson, Yap et al. 2004, Gratacap,
Guillermet-Guibert et al. 2011), the function of class II and class III PI3Ks in platelets is
not well established.

The role of class I PI3K isoforms in platelet plug formation
Human and mouse platelets contain all isoforms of class I PI3K including α, β,
and γ, and even small amounts of PI3K-δ (Vanhaesebroeck, Welham et al. 1997, Zhang,
Vanhaesebroeck et al. 2002, Watanabe, Nakajima et al. 2003, Jackson, Yap et al. 2004).
The binding of collagen to the platelet GPVI receptor leads to the phosphorylation of the
receptor’s FcRγ chain, which allows it to bind to the SH2 domain of PI3K-α, PI3K-β and
PI3K-δ (Falet, Barkalow et al. 2000, Watanabe, Nakajima et al. 2003). Conversely,
activation of the P2Y12 receptor leads to the release of the Gβγ subunit from
heterotrimeric G-proteins that binds the p101 subunit of PI3K-γ and activates this lipid
kinase complex (Heraud, Racaud-Sultan et al. 1998, Trumel, Payrastre et al. 1999)
(Kauffenstein, Bergmeier et al. 2001). Activation of all type I PI3Ks lead to the synthesis
of PtdIns(3,4,5)P3, which in turn activate the protein kinase, Akt (Chen, De et al. 2004,
Woulfe, Jiang et al. 2004) in platelets. In addition, PtdIns(3,4,5)P3 also facilitates the
activation of PLC-γ (Gilio, Munnix et al. 2009). Together, these signaling events have
	
  

12	
  

been shown to contribute to the activation of the small GTPase Rap1b, which is an
activator of integrin αIIbβ3 (Canobbio, Stefanini et al. 2009).
Initial studies using PI3K inhibitors that block all isoforms of PI3K such as
wortmannin and LY294002 suggested that PI3K is crucial for platelet adhesion and
aggregation under high shear (Yap, Anderson et al. 2002, Kasirer-Friede, Cozzi et al.
2004). However, the exact contribution of individual isoforms of PI3K during platelet
activation remained largely unknown. Over the past few years, studies using isoformspecific targeted mouse models and PI3K inhibitors provided strong evidence that the
different isoforms of class I PI3K have distinct cellular and physiological functions in
diverse cell types including in platelets. For instance, it is now established that PI3K-α is
crucial for cell growth and survival. This has implications in oncogenesis, and targeting
of PI3K-α is being investigated as a strategy for chemotherapeutics (Stephens, Williams
et al. 2005). Conversely, PI3K-γ plays an essential role in innate immunity and
inflammatory responses (Camps, Ruckle et al. 2005, Ruckle, Schwarz et al. 2006) while
PI3K-δ is crucial for adaptive immunity involving B and T cells and mast cells
(Okkenhaug and Vanhaesebroeck 2003, Ali, Bilancio et al. 2004). In platelets, PI3K-δ
knockout mice and kinase-deficient PI3K-δ knockin mice have only a minor defect in the
GPVI-mediated activation of integrin αIIbβ3(Senis, Atkinson et al. 2005). This implies
that other PI3K isoforms are the major mediators of collagen-induced platelet adhesion
and aggregation. Remarkably, in vivo inhibition of PI3K-β impairs the formation of
stable αIIbβ3-mediated platelet adhesion and prevents thrombus formation in mice, even
though it does not increase the bleeding time (Vanhaesebroeck, Ali et al. 2005). This
finding suggests that drugs that inhibit PI3K-β might not cause significant hemorrhage
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when given to patients for brief periods of time, such as during cardiac catheterization
(Jackson and Schoenwaelder 2006). Similarly, mice lacking PI3K-γ have defective
platelet aggregation upon stimulation with the platelet agonist ADP. Moreover, these
mice are less prone to form thrombi in response to intravenous injections with ADP. It
should be noted that these mice do not have spontaneous bleeding, again suggesting that
PI3K-γ might be a viable target for inhibiting thrombosis formation without inducing
excessive hemorrhage (Hirsch, Bosco et al. 2001, Lian, Wang et al. 2005). Additional
studies support that the functional role of PI3K-β and PI3K-γ in platelets are both
required for ADP- or thromboxane A2- induced activation of the Rap1b (Canobbio,
Stefanini et al. 2009). However, only PI3K-β (and not PI3K-γ) was necessary for
collagen-stimulated signaling pathways that lead to Akt phosphorylation, Rap1b
activation, and platelet aggregation (Canobbio, Stefanini et al. 2009). Together, these
studies suggest a story that is similar to what is seen in PIP5KI isoforms. Even though all
PI3K class I isoforms can produce PtdIns(3,4,5)P3, the individual isoforms have nonredundant roles in platelets.

1.3) PtdIns(3,5)P2 and trafficking to the lysosome
Trafficking to the lysosome
Lysosomes are organelles essential for intracellular degradation and recycling.
However, recent studies indicate that lysosomes also play a critical role in cellular
metabolism, signaling, repair and secretion (Settembre, Fraldi et al. 2013). To carry out
these functions, lysosomes receive substrates from endocytosis, phagocytosis and
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autophagy. In addition, newly synthesized soluble and membrane-bound lysosomal
proteins are delivered from the TGN (trans-golgi network) to the lysosome (Saftig and
Klumperman 2009).
Endocytosis involves the internalization of substrates from the plasma and its
delivery to the lysosome passing through a series of endosomal intermediates (Luzio,
Parkinson et al. 2009). In this dynamic process, membranes and proteins are constantly
outgoing and incoming to undergo a gradual remodeling process called maturation
(Huotari and Helenius 2011). The different endosomal intermediates resulting from this
maturation process include early endosomes, and multivesicular bodies/late endosomes.
In multivesicular bodies, the internalized cargo destined for degradation is sorted into
intraluminal vesicles (Luzio, Piper et al. 2009). The more mature forms of multivesicular
bodies are called late endosomes. These endosomal intermediates can be distinguished by
their content, molecular make-up, morphology, pH and kinetics of endocytic tracers
(Saftig and Klumperman 2009). Subsequently, the limiting membranes of late endosomes
fuse with lysosomes to form an intermediate structure called hybrid organelles. This
process is called endosome-lysosome fusion (Luzio, Pryor et al. 2007). This fusion
process requires well-coordinated activities of different protein complexes involved in the
biogenesis of late endosomes, endosome-lysosome tethering and endosome-lysosome
fusion. These protein complexes include the ESCRT (endosomal sortin complex required
for transport), HOPS (homotypic fusion and vacuole protein sorting) and trans-SNARE
(soluble N-ethylmaleimide-sensitive factor-attachment protein receptor) complexes
(Luzio, Gray et al. 2010). The resulting hybrid organelles display markers of endosomes
and lysosomes. Eventually, the lysosome is recycled from the hybrid organelle by a
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maturation process that includes condensation of content, removal of non-lysosomal
membrane proteins and recycling of SNAREs (Luzio, Pryor et al. 2007).
Lysosomes can receive substrates from the extracellular or intracellular sources.
During endocytosis, extracellular substrates are internalized and their luminal contents
are delivered to the lysosome for degradation. During autophagy, the intracellular
organelles are internalized to form autophagosomes, which fuse with lysosomes to form
autolysosomes for the degradation of their luminal contents.

To carry out these

degradative functions, it is essential that lysosomes receive the necessary soluble
hydrolytic enzymes and membrane-bound lysosomal proteins delivered through the
biosynthetic pathway.
The delivery of newly synthesized proteins from the TGN to the lysosome can be
direct or indirect (Saftig and Klumperman 2009). The direct pathway is used by many of
the hydrolases. They are synthesized in the ER, become labeled with mannose-6phosphate (M6P) in the cis-Golgi complex and subsequently bind to mannose-6phosphate-receptor (M6PR) in the TGN (Kornfeld 1987). M6PR recruits adaptor proteins
such as AP1 (adaptor protein-1) or GGA proteins that bind to clathrin to form clathrincoated vesicles. These vesicles enter the endosomes where the M6PR-bound hydrolase is
released as a result of low pH and M6PR is recycled to TGN. The released hydrolases are
subsequently transported to the lysosome. The direct pathway is also used by some
lysosomal membrane proteins (LMP) but they do not require binding to M6PR.
The indirect pathway is less understood and involves trafficking from the TGN to
the plasma membrane by a default secretory pathway, followed by an endocytic pathway
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to culminate in the lysosome. Many LMP use this pathway. LMP are synthesized in the
ER, trafficked to the TGN where they are secreted to the plasma membrane by a default
secretory pathway. On the plasma membrane, these proteins bind to AP2 (adaptor
protein-2) and are endocytosed to be sorted to the lysosome (Janvier and Bonifacino
2005). Unlike other hydrolases, β-glucocerebrosidase (βGC) follows the indirect pathway
by binding to LIMP2. βGC is not labeled by M6P in cis-Golgi and it binds to LIMP2 in
the TGN to continue on the indirect pathway via the plasma membrane.

PIKfyve complex and PtdIns(3,5)P2 metabolism
PtdIns(3,5)P2 is a phosphoinositide of low abundance that represents only about
0.0001% of total lipids in human erythrocytes (Lemmon 2008). This is about 500 fold
lower in comparison to PtdIns(4,5)P2 level. The presence of PtdIns(3,5)P2 was first
detected in 1997 in yeast and mammalian cells (Dove, Cooke et al. 1997) (Whiteford,
Brearley et al. 1997). PtdIns(3,5)P2 is synthesized from PtdIns(3)P on the endosomal
compartments in mammalian cells by the PtdIns(3)P 5-kinase PIKfyve (also known as
FAB1 in yeast) (Shisheva 2008). Currently, PIKfyve is thought to be the exclusive
enzyme for synthesis of PtdIns(3,5)P2. This notion is supported by genetic studies in
yeast showing a complete ablation of PtdIns(3,5)P2 synthesis in Fab1-null mutants
(Cooke, Dove et al. 1998).
Although PIKfyve is the exclusive kinase that synthesizes PtdIns(3,5)P2, the
kinase activity of PIKfyve is tightly regulated by other proteins that form a complex with
PIKfyve. These proteins include the PtdIns(3,5)P2 5-phosphatase Fig4 (also known as
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SAC3) (Gary, Sato et al. 2002, Sbrissa, Ikonomov et al. 2007) and the docking protein
VAC14 (also known as ArPIKfyve) (Jin, Chow et al. 2008, Sbrissa, Ikonomov et al.
2008). Although Fig4 can dephosphorylate PtdIns(3,5)P2 to PtdIns(3)P in vitro, the
ablation of Fig4 in vivo impairs the PIKfyve-mediated synthesis of PtdIns(3,5)P2, which
demonstrates the essential role of Fig4 in the stabilization of PIKfyve complex for its
proper kinase activity (Chow, Zhang et al. 2007, Ikonomov, Sbrissa et al. 2009).
Similarly, VAC14 is essential for the kinase activity of PIKfyve complex and mice
lacking VAC14 have defective synthesis of PtdIns(3,5)P2 (Zhang, Zolov et al. 2007, Jin,
Chow et al. 2008).

PtdIns(3,5)P2 effector proteins
PtdIns(3,5)P2 may execute its cellular functions by interacting with proteins
containing PtdIns(3,5)P2-specific binding domain. ATG18 in yeast (also known as
SVP1) is a multi-WD40 protein that fold as β-propeller (PROPPIN) that binds
PtdIns(3,5)P2 with high affinity (Kd ~500nM) and specificity (Dove, Piper et al. 2004).
In mammals, four homologues of ATG18 have been described. These include WIPI-1,
WIPI-2, WIPI-3 and WIPI-4 (Behrends, Sowa et al. 2010). WIPI-1 binds to PtdIns(3)P
and PtdIns(3,5)P2 (Jeffries, Dove et al. 2004, Proikas-Cezanne, Waddell et al. 2004).
Depletion of WIPI-1 and WIPI-2 lead to increased autophagosome number, suggesting
their essential role in autophagy suppression (Proikas-Cezanne and Robenek 2011). It is
currently unknown whether WIPI-3 and WIPI-4 bind to phosphoinositides and carry out
any functions in membrane trafficking.
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Although several other proteins have been proposed to be effector proteins of
PtdIns(3,5)P2, they bind PtdIns(3,5)P2 with significantly lower affinities compared to
Atg18. These candidate proteins include Tup1 (WD40 domain) (Han and Emr 2011),
Raptor (WD40 domain) (Bridges, Ma et al. 2012), SNX1 and SNX 2 (PX domain)
(Carlton, Bujny et al. 2004, Carlton, Bujny et al. 2005), Cti 6 (PHD domain), clavesin
(Sec14 domain) (Katoh, Ritter et al. 2009), and class II formins (PTEN domain) (van
Gisbergen, Li et al. 2012). In addition, PtdIns(3,5)P2 also binds and activates the ion
channels TRPML1 and RyR1 (Dong, Shen et al. 2010, Wang, Zhang et al. 2012), but the
lipid binding domain has not been identified in these proteins.

PtdIns(3,5)P2 functions
The cellular functions of Fab1 have been initially studied in yeast mutants lacking
Fab1 or its kinase activity. Fab1 mutant cells exhibit enlarged vacuoles and they are
defective in the retrograde trafficking from the vacuole to the late endosome, sorting into
the multivesicular bodies, and acidification of the vacuole (Gary, Wurmser et al. 1998).
Similarly, in mammalian cells , PIKfyve ablation by pharmacologic inhibition and siRNA
knockdown decreases the intracellular synthesis of PtdIns(3,5)P2 and cells exhibit
cytoplasmic vacuolation that express markers of early and late and/or lysosomes
(Ikonomov, Sbrissa et al. 2001, Rutherford, Traer et al. 2006, Jefferies, Cooke et al. 2008,
de Lartigue, Polson et al. 2009). Some studies using siRNAs-mediated knockdown of
PIKfyve demonstrated that PIKfyve is essential in the recycling of M6PR from
endosomes to the TGN (Rutherford, Traer et al. 2006, Zhang, Zolov et al. 2007, de
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Lartigue, Polson et al. 2009). Similarly, fibroblasts from Vac14 knockout mice are
deficient in the synthesis of PtdIns(3,5)P2 and they have impaired endosome-to-TGN
trafficking (Zhang, Zolov et al. 2007). However, other studies proposed that PIKfyve is
critical for the anterograde fusion of late endosomes with lysosomes. (Ikonomov, Sbrissa
et al. 2003, Rusten, Rodahl et al. 2006, Jefferies, Cooke et al. 2008). Consistent with
these findings, a study using PIKfyve inhibitor and siRNA knockdown showed that
salmonella containing vacuoles failed to fuse with the late endosome/lysosome for its
maturation (Kerr, Wang et al. 2010). This view is further supported by several studies
showing that PtdIns(3,5)P2-deficient cells accumulate autophagosomes because they fail
to mature into autophagolysosomes (Martin, Harper et al. 2013). These studies indicated
that the PIKfyve complex and its product PtdIns(3,5)P2 are essential regulators of
membrane homeostasis, and of vesicle trafficking and cargo transport along the
endosomal-lysosomal pathway (Dove, Dong et al. 2009, McCartney, Zhang et al. 2014) .
Recently, the physiological functions of PtdIns(3,5)P2 have been elucidated using
genetically engineered mice that lack different components of the PIKfyve complex
(Takasuga and Sasaki 2013). PIKfyve-null mice are embryonically lethal (Ikonomov,
Sbrissa et al. 2011), but mice expressing residual PIKfyve activity are viable and develop
defects within multiple organs, such as in the nervous, cardiopulmonary, and
hematopoietic systems (Zolov, Bridges et al. 2012). Similarly, Fig4-null mice or Vac14null mice develop several defects, including neurodegeneration, hypopigmentation, and
early lethality (Chow, Zhang et al. 2007, Zhang, Zolov et al. 2007). Notably,
homozygous Fig4 mutations were also identified in patients who have the
neurodegenerative diseases Charcot-Marie Tooth Syndrome 4J and Amyotrophic Lateral
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Sclerosis (Chow, Zhang et al. 2007, Chow, Landers et al. 2009), demonstrating a role for
PtdIns(3,5)P2 in neural development. More recently, a study using muscle-specific
PIKfyve knockout mouse showed that PIKfyve is essential for glucose homeostasis
(Ikonomov, Sbrissa et al. 2013). Furthermore, the loss of PIKfyve only in the intestinal
epithelial cells results in an inflammatory bowel phenotype demonstrating that PIKfyve is
essential for structural and functional integrity of intestinal epithelial cells (Takasuga,
Horie et al. 2013). Together, these studies indicate that PIKfyve has an essential and
distinct role in different types of tissues.

Purpose of the thesis research
In this thesis, my overall goal is to understand the biological role of PIKfyve in
platelets and in megakaryocytes using mice lacking PIKfyve only in these cell types.
Platelets are anucleated, but they store numerous biologically active substances in their
secretory organelles, which include alpha granules, dense granules, and lysosomes.
Platelet granules are generated in megakaryocytes from the endosomal-lysosomal system
(Heijnen, Debili et al. 1998, Youssefian and Cramer 2000, Ambrosio, Boyle et al. 2012,
Meng, Wang et al. 2012) by as yet, poorly understood mechanisms. Given the regulatory
role of PIKfyve synthesis of PtdIns(3,5)P2 in endosomal-lysosomal homeostasis and
trafficking pathway, we hypothesized that PIKfyve was essential for the biogenesis and
function of platelet granules. We show that PIKfyve is critical for proper lysosomal
homeostasis in platelets, but it is not necessary for the biogenesis of alpha granules or
dense granules. Remarkably, PIKfyve-null platelets are defective in the maturation,
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storage, and release of lysosomal enzymes. Unexpectedly, these platelet lysosomal
defects induce aberrant inflammatory responses in macrophages that impair the
development, body mass, fertility, and survival of mice.
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CHAPTER 2: MATERIALS AND METHODS
Animal models.
All animals were maintained on standard chow and tap water under specific
pathogen-free conditions. All animal procedures were approved by the Institutional
Animal Care and Use Committees at the University of Pennsylvania. Targeting of the
PIKfyve gene was generated using C57BL6 mice (inGenious Targeting Laboratory). A
bacterial artificial chromosome (BAC) derived from C57BL/6 (RPCI23) genomic DNA
was used to construct the targeting vector. The targeting vector was designed to excise
exons 37 and 38 of the mouse PIKfyve gene that encodes the activation loop of the kinase
domain. The 7.55 kb long homology arm extended 5’ to exon 37, and the 1.5 kb short
homology arm extended 3’ to exon 38. A pGK-gb2 loxP/FRT neocassette was inserted on
the 3’ side of exon 38, and the single loxP site was inserted at the 5’ side of exon 37. The
resulting 10.6 kb fragment was subcloned into an approximately 2.4 kb backbone vector
(pSP72, Promega) containing an ampicillin selection cassette to generate a final targeting
construct of 14.8 kb. C57BL/6 embryonic stem cells were electroporated with targeting
vectors. Clones resistant to the G418 antibiotic were selected and screened by Southern
Blot and PCR to identify recombinant ES clones. The selected clones were microinjected
into C57BL/6 blastocysts. Resulting chimeras with black coat color were mated with
wild-type C57BL/6 mice to generate PIKfyve F1 heterozygous offspring. F1
heterozygous mice were crossed with a FLP transgenic mouse to excise the neomycin
cassette that was flanked by FRT sites. The resulting F2 mosaic offspring were crossed
with wild-type mice to generate F3 heterozygotes that were missing the neomycin
cassette. F3 heterozygotes were crossed to generate mice carrying the PIKfyve floxed
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allele (PIKfyvefl). PIKfyvefl/fl mice were crossed with transgenic mice expressing Cre
recombinase under the control of the platelet factor 4 promoter (Pf4-Cre) to induce
tissue-restricted Cre recombination in the megakaryocyte lineage. For some experiments,
PIKfyvefl/fl mice were crossed with a B6;129S4-Gt(ROSA)26Sortm1Sor/J (Rosa26-LacZ)
reporter strain and then with a Pf4-Cre transgenic mouse. For other experiments,
PIKfyvefl/fl mice were crossed with B6-Cg-Pldnpa/J (pallid) mice, and their offspring were
paired with the Pf4-Cre transgenic mice to generate PIKfyvefl/fl Pf4-Cre/pallid mice. For
all studies, both female and male mice were used. Sex-matched littermates were used as
controls for all studies if not indicated otherwise.

PCR genotyping
Genomic DNA isolated from mouse tail biopsies was used to genotype mice by
PCR. The recombinant ES cells were identified with 5’CCAGAGGCCACTTGTGTAGC -3’ and 5’- CAGCCAGTGCTCGCATACAAAGG -3’
primers. The insertion of neomycin cassette in F1 mice was identified with 5’CCAGAGGCCACTTGTGTAGC -3’ and 5’- GGATGAAGTGCCTTGTTATCTGCAG 3’ primers. The 3rd LoxP integration was identified with 5’CCATTGCCTGGCTTAGAACAGAG -3’ and 5’-GAACTCTCCCGCGTAGTACAGC3’ primers. PCR generated products were either 310bp corresponding to the wild-type
alleles or 370bp corresponding to the targeted allele (LoxP integrated). Pf4-Cre transgene
was identified with 5’-CCCATACAGCACACCTTTTG-3’ and 5’TGCACAGTCAGCAGGTT-3’ primers. Rosa26/LacZ transgene was identified with 5’-
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AAAGTCGCTCTGAGTTGTTAT-3’, 5’-GCGAAGAGTTTGTCCTCAACC-3’ and 5’GGAGCGGGAGAAATGGATATG-3’.

Body composition analysis
Mice were anesthesized with sodium pentobarbital (90 mg per kg) and scanned by
dual energy X-ray absorptiometry (DEXA) at the Mouse Metabolism Core at the
University of Pennsylvania.

Histochemistry and immunohistochemistry
Necropsies were performed on female and male control and PIKfyvefl/fl Pf4-Cre
mice between 3 weeks and 28 weeks of age. They included macroscopic observations,
body and organ weight measurements, complete blood counts, serum chemistry analysis,
and microscopic examination of the brain, thymus, lymph nodes, heart, lung, small
intestine, large intestine, liver, spleen, pancreas, kidney, ovaries, testis, skin, muscle, fat,
and bone marrow. Fresh postmortem tissues were fixed overnight in 10% formalin,
paraffin-embedded and sectioned. Paraffin-sections were deparaffinized with xylene and
ethanol, and stained with hematoxylin/eosin, PAS, and Alcian Blue. For
immunohistochemistry, paraffin sections were deparaffinized with xylene and ethanol,
and antigen retrieved in 0.01M citrate buffer by microwaving for 30 minutes. They were
stained with the following primary antibodies: F4/80 (Serotec; 1:100), CD41 (BD
Pharmingen; MWReg30; 1:50), and CD45R/B220 (BD Pharmingen; RA3-6B2; 1:500).
Sections were counterstained with hematoxylin. For X-gal staining, frozen tissue sections
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were fixed with 0.5% glutaraldehyde for 10 minutes, and stained overnight with the
chromogenic substrate for β-galactosidase, X-gal (Cell Center, University of
Pennsylvania). Sections were then counterstained with hematoxylin or hematoxylin/eosin
as indicated.

Immunoblotting
Tissues were harvested and homogenized in RIPA buffer with a protease inhibitor
cocktail (Roche). The protein concentrations were determined using the BCA Protein
Assay (Pierce). Proteins were separated on SDS-PAGE gradient gels (Invitrogen) and
then transferred onto the polyvinylidene difluoride membrane (Invitrogen). The
membrane was blotted with the indicated primary antibodies against: PIKfyve-N-terminal
(Sigma-Aldrich; P0054; 1:400), LAMP-1 (Developmental Studies Hybridoma Bank;
1:1000), EEA-1 (Santa Cruz; 1:1000), Cathepsin D (Calbiochem; 1:1000), vWF (DAKO;
1:1000), PF4 (Bethyl; 1:1000), Akt (Cell Signaling Technology; 1:1000), pAkt (Cell
Signaling Technology; 1:1000), and b-actin (Cell Signaling Technology; 1:1000). This
was followed by blotting with horseradish peroxidase-conjugated secondary antibodies
and developing with enhanced chemiluminescence substrate (GE Healthcare).

Megakaryocyte and platelet preparation
Megakaryocytes were derived from the bone marrow by flushing mouse femurs
and cultured in the presence of 1% thrombopoietin (TPO, R&D Systems) in IDMD
supplemented with 10% FBS (Josefsson, James et al. 2011). After 4 days, cultured
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megakaryocytes were isolated by sedimentation through a 1.5% / 3% BSA step gradient.
To prepare washed platelets, blood was collected from the inferior vena cava of mice into
0.1 volume of acid citrate dextrose buffer. Platelet-rich plasma was separated by
centrifugation at 200 g for 10 minutes and incubated with 1 µM prostaglandin E1 for 10
minutes at room temperature. Platelets were then isolated by centrifugation at 800 g for
10 minutes and resuspended in HEPES-Tyrode buffer pH 7.4.

Megakaryocyte number and ploidy analysis
To measure the number of megakaryocytes in the bone marrow, isolated
megakaryocytes from the bone marrow were stained with CD41 antibody conjugated
with Alexa 488 (BD Biosciences), and cells were counted on the FACS Calibur flow
cytometer (BD Biosciences) discriminating size to subtract out platelets. To determine
the megakaryocyte ploidy, cells were stained with propidium iodide (Sigma) and the
relative DNA content was measured. FlowJo software was used to analyze all flow
cytometry data.

P-selectin expression analysis
Platelets were diluted to a density of 5 x 106 cells ml-1, stimulated with thrombin
at indicated concentrations and then incubated with a phycoerythrin-conjugated Pselectin antibody (BD Pharmingen). Fluorescence values were analyzed on a FACS
Calibur flow cytometer (BD Biosciences).
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Platelet aggregation and ATP secretion
Platelets were diluted to a density of 2.5 x 106 cells ml-1 in HEPES-Tyrode buffer
pH 7.4. Platelet aggregation in response to agonist stimulation was assessed by changes
in light transmission detected by a dual-channel lumi-aggregometer (Chrono-Log) with
stirring at 37 oC. Platelet secretion of ATP was assessed concurrently by the
luciferin/luciferase reaction after adding chrono-lume no. 395 (Chronolog) to the
aggregometer cuvette.

Transmission electron microscopy
Megakaryocytes grown in culture were harvested on day 6 and fixed in
glutaraldehyde. Ultrathin sections were obtained and collected on hexagonal copper
grids. Sections were stained with Reynold’s lead citrate and examined using transmission
electron microscopy at the Electron Microscopy Core Facility at the University of
Pennsylvania.

Platelet depletion in vivo
To study the effects of platelet depletion in the control mice and the PIKfyve fl/fl
Pf4-Cre mice, female and male mice at 8-10 weeks of age were administered with GPIbα
antibody (Emfret) at 2 µg per g twice weekly by intraperitoneal injections for a total of 6
weeks. Blood counts were monitored weekly by collecting blood from the retro-orbital
sinus. Body weight was monitored twice weekly. Necropsies were performed at the
completion of 6 weeks of antibody treatment.
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Radiation bone marrow chimeras
Bone marrow cells were isolated from wild-type mice expressing either CD45.1
or CD45.2 congenic markers or from PIKfyvefl/fl Pf4-Cre mice expressing CD45.2
congenic markers. Bone marrow cells were depleted of T cells and red blood cells by
using magnetic beads bound to antibodies against Ter119, CD3, CD4, and CD8. To study
the phenotype rescue effect, PIKfyvefl/fl Pf4-Cre recipient mice expressing CD 45.2
congenic markers were irradiated with 900 rads and administered by retro-orbital
injection with 2x106 bone marrow cells from wild-type mice expressing CD 45.1
markers. To study the phenotype transfer effect, wild-type recipient mice expressing
CD45.1 markers were irradiated with 900 rads, and administered by retro-orbital
injection with 1x106 bone marrow cells from wild-type mice expressing thy 1.1 marker
and 1x106 bone marrow cells from PIKfyvefl/fl Pf4-Cre mice expressing CD 45.2 markers.
Transplanted mice were maintained in sterile water with sulfamethoxazole/trimethoprim
for 3 weeks. Mice were sacrificed, and analyzed for engraftment and histology analyses
at about 33-35 weeks after transplantation.

β-hexosaminidase and cathepsin D activity assays
The β-hexosaminidase activity was determined using a chromogenic substrate
(Holmsen and Dangelmaier 1989). Mouse platelets or plasma were mixed with 10 mM
substrate p-nitrophenyl-N-acetyl-β-D-glucosaminide (Sigma) in citrate-phosphate buffer
pH 4.5. Platelet extracts were incubated for 16 hours at 37 oC, and plasma was incubated
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for 1 hour at 37 oC. The enzymatic reaction was stopped by the addition of 0.5 M NaOH.
The absorbance of released p-nitrophenolate was read at 405 nm in an ELISA plate
reader. Cathepsin D activity was determined using a fluorogenic substrate(Yasuda,
Kageyama et al. 1999). The reaction mixture contained 10 µl of platelet lysate solution,
10 µl of 200 µM of substrate Bz-Arg-Gly-Phe-Phe- Pro-4MeOβNA (Calbiochem), and 80
µl of 50 mM sodium acetate buffer pH 4.0. Reaction mixtures were incubated for 30
minutes at 37 oC. The enzymatic reaction was stopped by adding 5% TCA. The release of
2-naphthylamine was measured in a spectrofluorometer at emission wavelength 410 nm
and excitation wavelength 335 nm.

FeCl3-induced carotid artery thrombosis assay2
Mice were anesthetized using sodium pentobarbital (90 mg kg-1). A midline
incision was made in the neck, and the carotid artery was exposed and dissected away
from surrounding tissue. The artery was placed on a Doppler flow probe (Transonic
Systems, Ithaca, NY) to monitor blood flow through the vessel. After a baseline flow
measurement was recorded, vascular injury was initiated by placing a 1 mm2 piece of
filter paper saturated with 7.5% FeCl3 (Sigma) on the surface of the artery for 2 minutes.
The filter paper was then removed and the artery rinsed with saline, followed by the
continuous recording of blood flow in the vessel for 20 minutes post-injury. The time to
vessel occlusion was recorded.

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   	
  
2

This assay was performed in collaboration with Dr. Timothy Stalker, PhD at the University of
Pennsylvania.
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Plasma vWF analysis
For analysis of plasma vWF multimer distribution, mouse plasma (10 µl) was
denatured at 60 oC for 20 minutes with 10 µl of sample buffer (70mM Tris, pH 6.8, 2.4%
SDS, 0.67 M urea, 4 mM EDTA, 10% glycerol, 0.01% bromophenol blue). Proteins were
fractionated on 1% agarose gel on ice and transferred to a nitrocellulose membrane. The
membrane was blotted with vWF IgG antibody (Dako; 1:5000) to detect the vWF
multimers. For quantification analysis of plasma vWF antigen, we performed ELISA. A
microtiter plate coated with rabbit anti-vWF IgG (Dako; 1:2000) was incubated with
diluted mouse plasma for 1 hour at room temperature. After washing with PBS, bound
vWF was determined by peroxidase-conjugated rabbit anti-vWF IgG (Dako; 1:2000). A
pre-mixed TMB (3,3’,5,5’-tetramethylbenzidine) solution was used for color
development. The absorbance at 450 nm was determined by an ELISA plate reader.

Mass spectrometry analysis3
For the mass spectrometry analysis, platelets were isolated from three control
mice and three PIKfyvefl/fl Pf4-Cre mice. To prepare platelet releasates, washed platelets
(5 x 108 cells ml-1) were stimulated with 1 U ml-1 thrombin for 10 minutes at 37 oC.
Activated platelets were centrifuged at 13,000g for 10 minutes at 4 oC and the supernates
were isolated from the pellets. The concentrations of proteins from the platelet supernates
were measured using the BCA protein assay (Pierce). Proteins (40 µg) were digested with
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   	
  
3	
  The

proteomics analysis and its statistical analysis were performed in collaboration with Dr. Steven
Seeholzer, PhD and Mr. Chris McKennan at the Proteomics Core in The Children’s Hospital of
Philadelphia.	
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trypsin in solution. Tryptic digests were analyzed by LC-MS/MS on a hybrid LTQ
Orbitrap Elite mass spectrometer (Thermofisher Scientific San Jose, CA) coupled with a
nano LC Ultra (Eksigent). Peptides were separated by reverse phase (RP)-HPLC on a
nanocapillary column, 75 µm id × 15 cm Reprosil-pur 3 µM (Dr. Maisch, Germany) in a
Nanoflex chip system (Eksigent). Mobile phase A consisted of 1% methanol
(Fisher)/0.1% formic acid (Thermo) and mobile phase B of 1% methanol/0.1% formic
acid/80% acetonitrile. Peptides were eluted into the mass spectrometer at 300 nl min-1
with each RP-LC run comprising a 90 minute gradient from 10 to 25% B in 65 min, 2540% B in 25 min. The mass spectrometer was set to repetitively scan m/z from 300 to
1800 (R = 240,000 for LTQ-Orbitrap Elite) followed by data-dependent MS/MS scans on
the twenty most abundant ions, with a minimum signal of 5000, dynamic exclusion with
a repeat count of 1, repeat duration of 30 s, exclusion size of 500 and duration of 60 s,
isolation width of 2.0, normalized collision energy of 33, and waveform injection and
dynamic exclusion enabled. FTMS full scan AGC target value was 1e6, while MSn AGC
was 1e4, respectively. FTMS full scan maximum fill time was 500 ms, while ion trap
MSn fill time was 50 ms; microscans were set at one. FT preview mode; charge state
screening, and monoisotopic precursor selection were all enabled with rejection of
unassigned and 1+ charge states.
For database search, MS/MS raw files were searched against a mouse protein
sequence database including isoforms from the Uniprot Knowledgebase
(taxonomy:10090 AND keyword: "Complete proteome [KW-0181]") using MaxQuant
version 1.4.1.2 with the following set parameters: Fixed modifications, Carbamidomethyl
(C); Decoy mode, revert; MS/MS tolerance ITMS, 0.5 Da; false discovery rate for both
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peptides and proteins, 0.01; Minimum peptide Length, 6; Modifications included in
protein quantification, Acetyl (Protein N-term), Oxidation (M); Peptides used for protein
quantification, Razor and unique. The numbers of peptide spectral matches to each
protein were used for quantitative comparison between samples.
For quantification and statistical analysis of mass spectrometry data, we adapted a
method proposed by Choi(Choi, Fermin et al. 2008) to use a label free model using the
number of peptide spectral matches (PSMs) in each protein to determine the likelihood
that the protein was differentially regulated across the control mice and the knockout
mice. The idea is to develop a control model and a knockout model, and for each protein,
to test whether the knockout model describes its expression data significantly better than
the control model. To do so, we estimate a Bayes Factor !! =

! ! ! |!"#"
! ! ! |!"#"

for each

protein. We assume that the number of PSMs for protein ! in sample ! can be modeled as
a Poisson distribution with mean λ!,! , since each element !!,! in the PSM data matrix ! is
count data. To combat the limited number of biological replicates in each treatment
group, we pooled information across replicates and estimate each λ!,! using a control and
knockout hierarchical log-linear model, denoted by:
!! : !"# λ!!,! = !!" !! + !"# !! + !! + !!
(1)
!! : !"# λ!!,! = !"# !! + !"# !! + !! + !! + !! !!
(2)
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where !! is the length of protein !, !! is the mean number of spectral counts in
sample !, !! =

0  !"  sample  !  is  a  control  mouse
, ! is a model constant, !! is a
1  !"  sample  !  is  a  knockout  mouse   !

protein’s native expression term, and !! is a protein’s knockout expression term. We give
the model a well-defined structure by putting priors on !! ~! 0, !! ! , !! ~! 0, !! ! , and
!! ~! 0, !! ! . To make data-driven estimates of !! ! and !! ! , we place hyper priors on
these two parameters, given by !! ! , !! ! ~InvGamma(0.1, 0.1). We let !! “float”, and
thus set !! ! = 10! . We use these parameters (denoted as a vector by !) to estimate a
protein’s Bayes Factor:
! ! ! |!

!! = !

! ! |!

=

! ! ! ! ,!! ! !! ! ! !!! !(! ! )
! ! ! ! ,!! ! !! ! ! !!! !(! ! )

=

!!! |!! ! ! ! ! ,!!

(assuming we

!!! |!! ! ! ! ! ,!!

have no prior knowledge of P(!! ) and P(!! ) for any protein)  =

!
!
!
!"#!→!
!

!"#!→!

! !
!!!

! ! ! ,!!
!

! !
!!!

! ! ! ,!!
!

(3)
where the transition states !! → !!!! are determined using Metropolis Hastings
and Gibbs Sampling Markov Chain Monte Carlo techniques. Specifically, at iteration !
with parameter vector !!! (we explain using the knockout model, since !! ⊂ !! ),
P !! ! ∙   α  P ! !! ! ,∙ P !! ! = N !! ! ; 0, !! !

!

! Poisson

!!,! !! ! ,∙

(4)
P !! ! ∙   α  P !!,. !! ! ,∙ P !! ! = N !! ! ; 0, !! !
(5)
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! Poisson

!!,! !! ! ,∙

P !! ! ∙   α  P !!,. !! ! ,∙ P !! ! = N !! ! ; 0, !! !

! Poisson

!!,! !! ! ,∙

(6)
P !! ! ! ∙   α  P

!!

P !! ! ! ∙   α  P

!!

!
!!!

!

!! ! ! P !! ! ! = InvGamma 0.1 + ! , 0.1 +

!
!
!!! !!

!

(7)
!
!!!

!

!! ! ! P !! ! ! = InvGamma 0.1 + ! , 0.1 +

!
!
!!! !!

!

(8)
where G = #proteins.
The fold change for protein 'P' is defined as:
!!!! !!!! !!!!
!!! + !!! + !!!
Fold  change  P =
  
!!!"! !!!"! !!!"!
!!"! + !!"! + !!"!
where SC_ki is the number of spectral counts for protein 'P' in knockout replicate 'i', N_ki
is the average number of spectral counts in knockout replicate 'i', SC_wti is the number of
spectral counts for protein 'P' in wild type replicate 'i', and N_wti is the average number
of spectral counts in wild type replicate 'i'. To minimize the bias in the number of spectral
counts across conditions due to protein amount or machine performance, 6 different mass
spectrometry runs were carried out and each run was normalized to the mean number of
spectral counts in that run. In addition, to reduce the bias in the number of spectral counts
caused by the length of a protein, the spectral counts were also normalized to the length
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of protein (longer proteins tend to have more tryptic fragments and thus more spectral
counts).
To determine the set of proteins that significantly changed in the knockout set
with respect to the control set, we imposed a strict cutoff and required that each protein
have a Bayes Factor of at least 8 and a fold change of at least 2.0.

Statistical analysis
GraphPad Prism 5 was used to analyze data. All data are presented as mean ±
S.D. Two-tailed Student’s t-tests were used for the comparison of two groups. A log rank
test was performed for Kaplan Meier survival analysis. P-values of <0.05 (*), <0.01 (**),
and < 0.001(***) were used to ascertain statistical significance
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Introduction
Phosphoinositides are minor components of membrane phospholipids, yet they
are essential for the regulation of diverse cellular processes, including signal
transduction, cytoskeletal control, and membrane trafficking (Di Paolo and De Camilli
2006). Phosphoinositide metabolism is tightly modulated by specific lipid kinases and
phosphatases. Altering phosphoinositide turnover by dysregulating these enzymes can
lead to a variety of human diseases (McCrea and De Camilli 2009).
PtdIns(3,5)P2 is a phosphoinositide of low abundance that is synthesized from
PtdIns(3)P on the endosomal compartments in mammalian cells by the lipid kinase
PIKfyve (also known as FAB1)(Shisheva 2008). PIKfyve forms a protein complex with
other regulatory proteins, such as the PtdIns(3,5)P2 5-phosphatase Fig4 (also known as
SAC3) (Gary, Sato et al. 2002, Sbrissa, Ikonomov et al. 2007) and the docking protein
Vac14 (also known as ArPIKfyve) (Jin, Chow et al. 2008, Sbrissa, Ikonomov et al. 2008).
The PIKfyve complex and its product PtdIns(3,5)P2 are essential regulators of membrane
homeostasis, and of vesicle trafficking and cargo transport along the endosomallysosomal pathway (Dove, Dong et al. 2009, McCartney, Zhang et al. 2014) .
Recently, physiological functions of PtdIns(3,5)P2 have been elucidated using
genetically engineered mice that lack different components of the PIKfyve complex
(Takasuga and Sasaki 2013). PIKfyve-null mice are embryonically lethal(Ikonomov,
Sbrissa et al. 2011), but mice expressing residual PIKfyve activity are viable and develop
defects within multiple organs, such as in the nervous, cardiopulmonary, and
hematopoietic systems (Zolov, Bridges et al. 2012). Similarly, Fig4-null mice or Vac14	
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null mice develop several defects, including neurodegeneration, hypopigmentation, and
early lethality (Chow, Zhang et al. 2007, Zhang, Zolov et al. 2007). Notably,
homozygous Fig4 mutations were also identified in patients who have the
neurodegenerative diseases Charcot-Marie Tooth Syndrome 4J and Amyotrophic Lateral
Sclerosis (Chow, Zhang et al. 2007, Chow, Landers et al. 2009), demonstrating a role for
PtdIns(3,5)P2 in neural development. Although studies showed that PtdIns(3,5)P2
deficiency causes defects in multiple cellular pathways including those required for
endolysosomal trafficking in yeast and mammalian cell cultures, the physiological
consequences of PtdIns(3,5)P2 in non-neural cells, such as those of the hematopoietic
system, are not well understood.
Platelets are hematopoietic cells that are crucial for hemostatic plug formation in
response to vascular injury. This process has been shown to require a series of key
platelet activation events that are tightly regulated by several phosphoinositides (Min and
Abrams 2013). However, the regulatory role of PtdIns(3,5)P2 in platelets remains
unknown. Platelets are anucleated, but they store numerous biologically active substances
in their secretory organelles, which include alpha granules, dense granules, and
lysosomes(King and Reed 2002, Whiteheart 2011). Platelet granules are generated in
megakaryocytes from the endosomal-lysosomal system (Heijnen, Debili et al. 1998,
Youssefian and Cramer 2000, Ambrosio, Boyle et al. 2012, Meng, Wang et al. 2012) by
as yet, poorly understood mechanisms.
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In this study, we investigated whether PIKfyve plays an essential role in platelets
and in megakaryocytes using mice lacking PIKfyve specifically in these cell types. Given
the role of PIKfyve-mediated PtdIns(3,5)P2 production in the regulation of the
endosomal-lysosomal pathway, we hypothesized that PIKfyve was essential for the
biogenesis and function of platelet granules. We show that PIKfyve is critical for proper
lysosomal homeostasis in platelets, but it is not necessary for the biogenesis of alpha
granules or dense granules. Remarkably, PIKfyve-null platelets are defective in the
maturation, storage, and release of lysosomal enzymes. Unexpectedly, these platelet
lysosomal defects induce aberrant inflammatory responses in macrophages that impair
the development, body mass, fertility, and survival of mice.
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Loss of PIKfyve in platelets causes multiorgan defects
To investigate the role of PIKfyve in platelets and in megakaryocytes, we
generated mice lacking PIKfyve kinase activity specifically in these cell types. The
PIKfyve gene was conditionally targeted with loxP sites flanking the exons corresponding
to the kinase activation loop to generate floxed alleles of PIKfyve (PIKfyvefl, Fig. 3.1).
Mice expressing PIKfyvefl were crossed with transgenic mice expressing the Cre
recombinase that is controlled by the platelet-factor-4 promoter (Pf4-Cre), which restricts
the expression of Cre recombinase exclusively within megakaryocytes and their derived
platelets (Tiedt, Schomber et al. 2007).

Figure 3.1. Generation of the PIKfyvefl/fl
Pf4-Cre mouse. Schematic representation of
genetic targeting of PIKfyve. The target
exons 37 and 38 (red bars) were targeted
with lox P recombination sites (yellow
arrows) to generate PIKfyve floxed alleles
(PIKfyvefl). Mice expressing PIKfyvefl were
then crossed with Pf4-Cre mice to induce
homologous recombination of the PIKfyvefl
(PIKfyve Post-Cre).

PIKfyvefl/fl Pf4-Cre mice developed several morphological abnormalities relative
to their littermate PIKfyvefl/+ mice, PIKfyvefl/fl mice, and PIKfyvefl/+ Pf4-Cre mice. At
about 3 weeks of age, PIKfyvefl/fl Pf4-Cre mice exhibited mild growth delay and body
hair loss (Fig. 3.2a). Over time, they gradually developed coarse facial features,
abdominal distention, a generalized increase in the bulk of their soft tissues, and body
weight gain (Fig. 3.2b and 3.2c). Despite this weight gain, body composition analysis by
dual-energy X-ray absorptiometry showed that PIKfyvefl/fl Pf4-Cre mice had reduced
body fat, but increased lean body mass, as compared to their littermate controls (Fig.
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3.2d). In addition, they also had decreased bone mineral density (Fig. 3.2e). As PIKfyvefl/fl
Pf4-Cre mice aged, they remained infertile (Fig. 3.2f) and their general body functions
deteriorated. The vast majority died before 28 weeks of age (Fig. 3.2g).

Figure 3.2	
   Platelet-specific ablation of PIKfyve causes multiorgan abnormalities in
mice. (a) General appearance of PIKfyvefl/fl and PIKfyvefl/fl Pf4-Cre littermates at 3 weeks
of age. Note the characteristic hair loss and small size in the PIKfyvefl/fl Pf4-Cre mice. (b)
General appearance of control and PIKfyvefl/fl Pf4-Cre littermates at 24 weeks of age.
Note the characteristic coarse facial features, body hair loss, and severely distended body
morphology. (c) Body weight of control mice and PIKfyvefl/fl Pf4-Cre mice. The average
numbers of mice were 8 per time point and per group. (d) Percent of total body fat in the
control (n=3) and PIKfyvefl/fl Pf4-Cre (n=3) mice at 12-24 weeks of age. (e) Bone
mineral density of the control (n=3) and PIKfyvefl/fl Pf4-Cre (n=3) mice at 12-24 weeks
of age. ) (f) Number of pregnancies achieved by females (n=10) and by males (n=10)
over 4 months of mating period. (g) Survival curves of female and male control (n= 40)
and PIKfyvefl/fl Pf4-Cre (n= 40) mice. *P<0.05, ** P<0.01, ***P<0.001. All error bars
indicate mean ± S.D. Student’s t-test.
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PIKfyvefl/fl Pf4-Cre mice accumulate vacuolated macrophages
To elucidate the cause of multiorgan defects in PIKfyvefl/fl Pf4-Cre mice,
histological and immunohistochemical analyses were performed in mice of 3-28 weeks of
age. Unlike their control littermates, PIKfyvefl/fl Pf4-Cre mice exhibited massive
organomegaly (Fig. 3.3). This phenotype reflected progressive tissue infiltration by
engorged cells with multiple cytoplasmic vacuoles that had a “foamy” appearance (Fig.
3.4, arrowheads). Although the vacuoles of these cells did not stain with classical dyes
for proteins or lipids, their cytoplasm strongly stained with Alcian Blue and PAS,
suggesting an excessive storage of acidic polysaccharides in the vacuolated cells (Fig.
3.5a and 3.5b).

Figure 3.3. PIKfyvefl/fl Pf4-Cre mice develop
multiple organ defects. (a) Representative pictures
of the heart, lung, liver, and intestines in the control
PIKfyvefl/fl mice and in the PIKfyvefl/fl Pf4-Cre mice at
24 weeks of age.
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Figure 3.4. Inflammatory vacuolated macrophages infiltrate multiple tissues in the
PIKfyve fl/fl Pf4-Cre mice. Representative histopathology of the lung, liver, skin and
intestine from the control PIKfyvefl/fl mice and PIKfyvefl/fl Pf4-Cre mice at 24 weeks of
age. Insets show images in the boxed area at higher magnification. Hematoxylin and
eosin stain. Scale bar, 100µm, inset, 20µm. All arrowheads indicate the vacuolated cells.
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Figure 3.5. The aberrant macrophages with cytoplasmic vacuoles store acidic
mucosubstances. (a) Representative lung sections from the control and the PIKfyvefl/fl
Pf4-Cre mice were stained with Alcian Blue. Scale bar, 100µm. Inset shows higher
magnification of the boxed area. Scale bar, 20µm. (b) Representative liver sections from
the control and the PIKfyvefl/fl Pf4-Cre mice (n=3) were stained with PAS. Scale bar,
100µm. Inset shows higher magnification of boxed area. Scale bar, 20µm.

In their livers and lungs, the vacuolated cells accumulated in a perivascular distribution
and displaced the normal tissue, suggesting that the vacuolated cells originated from the
blood or vasculature. By immunohistochemical analysis, the vacuolated cells stained with
the macrophage-specific marker F4/80 (Fig. 3.6a), but not with the markers of other cell
lineages, including GPIb (a megakaryocyte-specific marker). The F4/80-positive
vacuolated macrophages in the livers of PIKfyvefl/fl Pf4-Cre mice were approximately 3-4
fold larger than the F4/80-positive macrophages in the livers of the control mice
(Fig.3.6b). In addition, tissues infiltrated with the vacuolated macrophages were often
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associated with mononuclear cell infiltrates that stained with the lymphocyte marker
CD45R (Fig. 3.6c), suggesting a local inflammatory response. These results demonstrate
that the loss of PIKfyve in platelets causes the invasion of normal tissues with
inflammatory vacuolated macrophages.

Figure 3.6. The infiltrating vacuolated cells are inflammatory F4/80+ macrophages.
(a) Liver structures of control mice and PIKfyvefl/fl Pf4-Cre mice were stained for
macrophages with anti-F4/80 antibody by immunohistochemistry. Scale bar, 100µm.
Inset shows higher magnification of the boxed area. Scale bar, 20µm. (b) Representative
lung sections from the control and the PIKfyvefl/fl Pf4-Cre mice were stained with antiCD45R/B220 antibody. Scale bar, 100µm. Inset shows higher magnification of the boxed
area. Scale bar, 20µm. All arrowheads indicate the vacuolated macrophages.
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PIKfyve-null platelets induce macrophage pathology
Cells from PtdIns(3,5)P2-deficient organisms have been shown to form large
cytoplasmic vacuoles(Takasuga and Sasaki 2013, McCartney, Zhang et al. 2014).
However, because our genetic approach was designed to only ablate PtdIns(3,5)P2
synthesis in platelets and in megakaryocytes, we did not expect to see the robust
cytoplasmic vacuolation in the macrophages of PIKfyvefl/fl Pf4-Cre mice. Therefore, we
further addressed whether these unexpected macrophage abnormalities resulted from
aberrant PIKfyve disruption in macrophages, or by non-autonomous effects of PIKfyve
disruption in platelets. Immunoblotting analysis showed that PIKfyve protein was absent
in platelets, but present in the liver, spleen, and lungs of PIKfyvefl/fl Pf4-Cre mice.
PIKfyve protein was also present in all tissues of the control mice (Fig. 3.7). These
results strongly suggest that the PIKfyve protein was ablated only in the megakaryocyte
lineage of PIKfyvefl/fl Pf4-Cre mice.

Figure 3.7. PIKfyve expression is absent exclusively in the platelets of PIKfyvefl/fl
Pf4-Cre mice. The levels of PIKfyve protein were determined in the platelets, liver,
spleen and lung of the indicated mice by immunoblotting. Note the absence of the
PIKfyve protein in the platelets, but its presence in the liver,spleen and lung of PIKfyvefl/fl
Pf4-Cre mice (n=3 per group). Tissues from the wild-type mice, the PIKfyvefl/+ Pf4-Cre
mice, and the PIKfyvefl/fl mice were used as positive controls. β-actin was used as a
loading control.
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Although Pf4-Cre expression has been shown to be restricted to megakaryocytes
and platelets (Tiedt, Schomber et al. 2007, Bertozzi, Schmaier et al. 2010, Carramolino,
Fuentes et al. 2010, Josefsson, James et al. 2011), we next re-evaluated Pf4-Cre
expression in PIKfyvefl/fl Pf4-Cre mice by crossing them to mice expressing a Credependent LacZ reporter (Rosa26-LacZ)(Soriano 1999). Tissue staining of PIKfyvefl/fl
Pf4-Cre/ Rosa26-Lacz mice with X-gal showed β-galactosidase expression only in
megakaryocytes and in platelets (Fig. 3.8a, arrows), but not in the vacuolated
macrophages or in other cells (Fig. 3.8b, arrowheads). This genetic evidence excludes the
possibility that Pf4-Cre induced PIKfyve ablation in the macrophages of PIKfyvefl/fl Pf4Cre mice. Together, these results demonstrate that the macrophage infiltration and
enlargement observed in PIKfyvefl/fl Pf4-Cre mice are indirectly induced by PIKfyve
ablation in megakaryocytes and/or in platelets.

Figure 3.8. Pf4-Cre is specifically
expressed in platelets and
megakaryocytes. (a) X-gal staining of
the lung tissues from PIKfyvefl/fl
Rosa26-LacZ mice and PIKfyvefl/fl Pf4Cre Rosa26-LacZ mice. Scale bar, 20
µm. The arrow indicates the platelet
clumps in the lung vessels expressing
LacZ (blue stain). Arrowheads indicate
the vacuolated macrophages that did
not stain blue. (b) Representative
pictures of X-gal staining of the spleen
sections from 10 week-old mice (n=5
per group). Arrows indicate
megakaryocytes. Note the expression
of LacZ (blue stain) only in the
megakaryocytes of PIKfyvefl/fl Pf4-Cre /
Rosa-LacZ mice. Scale bar, 20µm.
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To further address whether PIKfyve-null platelets contribute to the robust
macrophage response leading to the multiorgan failure in PIKfyvefl/fl Pf4-Cre mice, we
studied the effects of platelet depletion using monoclonal GP1bα antibodies(Bergmeier,
Rackebrandt et al. 2000, Nieswandt, Bergmeier et al. 2000). Platelet depletion was
initiated at 8-10 weeks of age. At that point, the PIKfyvefl/fl Pf4-Cre mice had already
developed body hair loss, some weight gain, and tissue infiltration of their vacuolated
macrophages. Control mice and PIKfyvefl/fl Pf4-Cre mice were either untreated or
administered GP1bα antibodies twice weekly via intraperitoneal injections for 6 weeks.
As reported previously, the injection of GP1bα antibodies efficiently induced acute
thrombocytopenia in both sets of mice(Bergmeier, Rackebrandt et al. 2000, Nieswandt,
Bergmeier et al. 2000). However, repetitive injections of GP1bα antibodies were less
effective at inducing stable thrombocytopenia over time likely because of the reactive
thrombocytopoiesis associated with complete platelet depletion with anti-platelet
antibodies(Trowbridge and Martin 1984). Nevertheless, the PIKfyvefl/fl Pf4-Cre mice that
were treated with GP1bα antibodies showed a significant delay in weight gain and
attenuated hair loss as compared to the untreated PIKfyvefl/fl Pf4-Cre mice (Fig. 3.9a and
3.9b). Together, our findings demonstrate that platelets are the primary contributors in the
development of the inflammatory macrophage response and multiorgan defects in
PIKfyvefl/fl Pf4-Cre mice.
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Figure 3.9. Platelets drive the multiorgan defects in the PIKfyvefl/fl Pf4-Cre mice.
(a) Representative general morphology of 15-weeks-old control mice and PIKfyvefl/fl Pf4Cre mice after 6 weeks of either no intervention (untreated) or biweekly injections of
anti-GP1bα antibodies (+GP1bα Ab). (b) Body weight change of the control mice and
PIKfyvefl/fl Pf4-Cre mice after 6 weeks of no intervention or treatment with anti-GP1bα
antibodies (n=3 for each group). *P<0.05. All error bars indicate mean ± S.D. Student’s
t-test.

	
  

50	
  

We also investigated whether the macrophage response in PIKfyvefl/fl Pf4-Cre
mice could be rescued or transferred by hematopoietic stem cell (HSC) transplantation.
Lethally irradiated wild-type mice of 8-12 weeks of age were reconstituted with a
mixture of donor cells that were half derived from PIKfyvefl/fl Pf4-Cre HSCs and half
derived from wild-type HSCs. Thirty-five weeks later, a necropsy showed that infiltration
of vacuolated macrophages was readily apparent in the liver, lung, colon, and bone
marrow of the irradiated wild-type recipient mice (Figure 3.10b and 3.10e, arrowheads).
Conversely, lethally irradiated PIKfyvefl/fl Pf4-Cre mice of 8-12 weeks of age were
reconstituted exclusively with wild-type donor HSCs. At about 8 weeks after
transplantation, the characteristic hair loss and weight gain were significantly attenuated.
A necropsy at 35 weeks after transplantation confirmed that the infiltration of the
vacuolated macrophages in multiple tissues was completely reversed (Supplementary Fig.
3.10c and 3.10f). Together, these results further demonstrate that the phenotype of
PIKfyvefl/fl Pf4-Cre mice can be either rescued or transferred by hematopoietic progenitor
cells.
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Figure 3.10. Transplanted bone marrow cells can recapitulate or revert the tissue
infiltration of vacuolated macrophages in PIKfyvefl/fl Pf4-Cre mice. (a-c) General
appearance of lethally irradiated recipient mice approximately 35 weeks after the
transplantation of hematopoietic stem cells (HSC). (a) Wild-type HSC were transplanted
into wild-type mice. (b) Mixture of HSC half derived from wild-type HSC and half
derived from PIKfyvefl/fl Pf4-Cre HSC were transplanted into wild-type mice (n=5 per
group). (c) Wild-type HSC were transplanted into PIKfyvefl/fl Pf4-Cre mice. (d-f) Liver
sections from the respective recipient mice in panels (a-c). Black arrowheads indicate the
vacuolated macrophages. White arrows indicate vessels. Scale bar, 20µm.
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Megakaryopoiesis and thrombopoiesis do not require PIKfyve
We next studied the effects of PIKfyve ablation in megakaryocytes of PIKfyvefl/fl
Pf4-Cre mice. Fibroblasts and neurons of PtdIns(3,5)P2-deficient organisms typically
develop large vacuoles(Takasuga and Sasaki 2013, McCartney, Zhang et al. 2014).
Histological analysis by light microscopy of bone marrow sections showed that PIKfyvenull megakaryocytes were morphologically indistinguishable from control
megakaryocytes (Fig. 3.11a). However, analysis by transmission electron microscopy of
cultured megakaryocytes derived from PIKfyvefl/fl Pf4-Cre bone marrow revealed
multiple enlarged cytoplasmic vacuoles (Fig. 3.11b). Despite this abnormality, flow
cytometric analysis showed no significant differences in the number of megakaryocytes
in the bone marrow of control or PIKfyvefl/fl Pf4-Cre mice (Fig. 3.11c). Moreover,
PIKfyve-null megakaryocytes had normal ploidy, implying that the loss of PIKfyve did
not affect megakaryocyte maturation (Fig. 3.11d). Finally, counts of platelets and
leukocytes as well as hemoglobin level were similar between control and PIKfyvefl/fl Pf4Cre mice (Fig.3.11e-g). Thus, PIKfyvefl/fl Pf4-Cre mice normally develop
megakaryocytes in vivo and produce normal numbers of platelets, and they also normally
develop other blood cells.
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Figure 3.11. PIKfyve is not necessary for the development of megakaryocytes nor
for platelet production. (a) Representative pictures of bone marrow sections from the
control and PIKfyvefl/fl Pf4-Cre mice at 16 weeks of age. White arrows indicate
megakaryocytes. Black arrowheads indicate the vacuolated macrophages. Scale bar
20µm. (b) Electron micrographs of megakaryocytes grown in culture in the presence of
thrombopoietin for 7 days. Note multiple enlarged vacuoles in the cytoplasm of
PIKfyvefl/fl Pf4-Cre mice as compared to the control mice. Scale bar, 10 µm. (c) CD41+
megakaryocyte counts of control and PIKfyvefl/fl Pf4-Cre mice (n=3 for each group). (d)
Megakaryocyte ploidy (n=3 for each group). (e-g) Counts of platelets (e), WBC (f), and
Hb (g) of control mice and PIKfyvefl/fl Pf4-Cre mice (n=3 for each group). All error bars
indicate mean ± S.D. Student’s t-test.
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PIKfyve regulates trafficking of platelet lysosomal cargoes
We next investigated the effects of PIKfyve ablation in the morphology and
functions of platelets in PIKfyvefl/fl Pf4-Cre mice. Transmission electron microscopy
demonstrated that in contrast to the PIKfyve-null megakaryocytes derived from the bone
marrow, the ultrastructure of PIKfyve-null platelets was indistinguishable from that of
control platelets (Fig. 3.12a). To test whether the loss of PIKfyve impacted granule
content, we assessed the abundance of representative components by immunoblotting.
PIKfyve-null platelets expressed normal levels of the alpha granule components von
Willebrand factor and platelet factor 4 (Fig. 3.12b-c). In contrast, PIKfyve-null platelets
exhibited increased levels of the lysosomal protein LAMP-1 (Lysosomal-Associated
Membrane Protein 1; Fig. 3.13a-b) and increased activity of the lysosomal enzyme βhexosaminidase (Fig. 3.13c). These results suggest that PIKfyve-null platelets store
normal levels of alpha granule components, but store excessive levels of lysosomal
components.

Figure 3.12. PIKfyve is not
required for the storage of
platelet alpha granules.
(a) Representative electron
micrographs of platelets
extracted from PIKfyvefl/fl and
PIKfyvefl/fl Pf4-Cre mice at 3
weeks of age. Scale bar 2µm.
(b) Immunoblot of platelet
lysates showing the expression
of vWF and Pf4 in the control
and PIKfyve-null platelets. βactin was used as a loading
control. (c) Quantification of
panel (c) (n=3). All error bars
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indicate mean ± S.D.
To test whether PIKfyve regulates granule secretion, we stimulated platelets ex
vivo and monitored granule release by surface expression of granule markers or release of
mediators into the medium. Following thrombin stimulation, PIKfyve-null platelets
translocated the α-granule protein P-selectin to their cell surface as efficiently as control
platelets (Fig. 3.14a). Likewise, ATP secretion from dense granules was similar in control
and PIKfyve-null platelets (Fig. 3.14b). However, the releasates from PIKfyve-null
platelets showed increased activity of the lysosomal enzyme, β-hexosaminidase (Fig.
3.13c).

Figure 3.13. PIKfyve is critical for proper storage and release of lysosomal proteins
in platelets. (a) Immunoblot of platelet lysates from the control mice and PIKfyvefl/fl
Pf4-Cre mice showing the expression of EEA-1 and LAMP-1. β-actin was used as the
loading control. (b) Quantification of protein bands shown in the panel a (n=3 for each
group). (c) β-hexosaminidase activity in the platelet lysates of control mice (n=3) and
PIKfyvefl/fl Pf4-Cre mice (n=3).
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Further analysis showed that the PIKfyve-null platelets released a normal
percentage of their total cellular β-hexosaminidase following agonist stimulation (Fig.
3.14c). These data indicate that PIKfyve-null platelets release higher levels of βhexosaminidase than the control platelets because they contain excessive amounts of this
lysosomal enzyme, and not because they secrete it more efficiently. Consistent with this
finding, β-hexosaminidase activity was found to also be elevated in the plasma of
PIKfyvefl/fl Pf4-Cre mice (Fig. 3.13c). Together, these findings demonstrate that PIKfyvenull platelets store and release excessive levels of lysosomal cargo proteins.

Figure 3.14. PIKfyve is not required for the efficient exocytosis of platelet granules.
(a) Platelet surface translocation of P-selectin upon stimulation with thrombin at shown
concentrations (n=3). (b) Representative graphs showing ATP secretion (green and black
lines) and aggregation (red and blue lines) of control platelets (black and blue lines) and
PIKfyve-null platelets (green and red lines). Platelets were stimulated with thrombin (1U
ml-1) or collagen (10µg ml-1). (c) ß-hexosaminidase activity in the platelet releasates and
lysates after stimulation with thrombin (1U ml-1), collagen (10µg ml-1), and ADP. White
portions of the bar represent the enzymatic activity in the platelet releasates following
platelet stimulation. Black portions of the bars represent the enzymatic activity in the
residual platelet lysates after stimulation (n=3 per group).
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To more comprehensively analyze how the loss of PIKfyve affects the contents
secreted upon platelet activation, a quantitative proteomics analysis was performed. By
tandem liquid chromatography- mass spectrometry (LC-MS/MS), we identified the
proteins released from the control platelets and the PIKfyve-null platelets following
thrombin stimulation. We then used the spectral counting of the identified peptides to
quantitatively compare the proteins released from the control platelets and the PIKfyvenull platelets. Using a cutoff of 2.0-fold as a significant difference between them, we
identified 17 proteins that were increased and 38 proteins that were decreased in the
releasates of PIKfyve-null platelets relative to wild-type platelets (Table 3.1 and 3.2).
Among those proteins that were more abundant in the PIKfyve-null platelet releasates,
several lysosomal enzymes stood out including cathepsin D, cathepsin B, and maltase
(Table 3.1). Remarkably, levels of the cathepsin D were 20-fold higher in PIKfyve-null
platelet releasates than in control releasates (Table 3.1).
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Gene
names
Ctsd
Saa1
Iglc3
Col1a1
Psmb1
Psma6
Fbln1
Lcat
C1qa
Cfp
Ctsb
Apob
Kng2
Krt14
Mgam
Itih3
C1sa

Protein names
Cathepsin D
Serum amyloid A-1 protein
Ig lambda-3 chain C region
Collagen alpha-1(I) chain
Proteasome subunit beta type-1
Proteasome subunit alpha type-6
Fibulin-1
Phosphatidylcholine-sterol acyltransferase
Complement C1q subcomponent subunit A
Properdin
Cathepsin B
Apolipoprotein B
Kininogen 2
Keratin, type I cytoskeletal 14
Maltase-glucoamilase
Inter-alpha-trypsin inhibitor heavy chain H3
Complement C1s-A subcomponent

Bayes
Fold Change
Factor
(KO/Cont)
(KO/Cont)
4757.53
20.28
266.90
15.48
263.45
14.34
116.35
12.79
37.79
11.06
23.52
9.82
10000.00
8.87
8932.21
6.49
18.07
3.46
749.23
3.21
14.55
3.21
10000.00
2.49
200.88
2.42
14.80
2.33
15.76
2.13
90.05
2.01
14.43
1.99

Table 1. Upregulated proteins in the platelet releasates of PIKfyvefl/fl Pf4-Cre mice.
The numbers of peptide spectral matches to each protein were used for quantitative
comparison between the knockout (KO) and control (Cont) platelet samples. A Bayes
Factor of at least 8 and a fold change of at least 2.0. were used for statistical analysis.
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Protein names
Tropomyosin alpha-4 chain
Myosin light polypeptide 6
Major urinary protein 20
Fermitin family homolog 3
Zyxin
Filamin-A
Coagulation factor XIII A chain
Apolipoprotein C-III
Beta-parvin
Protein disulfide-isomerase A3
Glyceraldehyde-3-phosphate dehydrogenase
Arachidonate 12-lipoxygenase, 12S-type
von Willebrand factor
Latent-transforming growth factor beta-binding
protein 1regulatory light polypeptide 9
Myosin
Interleukin-1 receptor accessory protein
Bridging integrator 2
Alpha-actinin-1
14-3-3 protein eta
Multimerin-1
Vinculin
L-lactate dehydrogenase A chain
Talin-1
Galectin-3-binding protein
Tubulin beta-4B chain;Tubulin beta-4A chain
WD repeat-containing protein 1
Transforming growth factor beta-1
Tubulin alpha-1B chain
Heat shock cognate 71 kDa protein
Myosin-9
Tubulin beta-1 chain
Glia-derived nexin
78 kDa glucose-regulated protein
Coagulation factor V
Metalloproteinase inhibitor 3
Afamin
Cofilin-1
14-3-3 protein zeta/delta

Gene
names
Tpm4
Myl6
Mup20
Fermt3
Zyx
Flna
F13a1
Apoc3
Parvb
Pdia3
Gapdh
Alox12
Vwf
Ltbp1
Myl9
Il1rap
Bin2
Actn1
Ywhah
Mmrn1
Vcl
Ldha
Tln1
Lgals3bp
Tubb4b
Wdr1
Tgfb1
Tuba1b
Hspa8
Myh9
Tubb1
Serpine2
Hspa5
F5
Timp3
Afm
Cfl1
Ywhaz

Bayes
Fold
Factor
Change
(KO/Cont)
10000.00 (KO/Cont)
-24.53
82.14
-12.77
83.75
-12.57
248.02
-12.55
254.52
-11.85
10000.00
-11.07
28.51
-10.91
139.36
-10.85
28.66
-10.68
80.52
-10.15
1515.81
-9.97
17.36
-9.42
10000.00
-7.77
1574.75
-6.72
404.59
-6.62
1016.67
-6.18
250.57
-6.09
10000.00
-5.84
14.60
-5.34
10000.00
-5.09
10000.00
-4.69
224.16
-4.63
10000.00
-4.53
738.58
-4.36
760.98
-4.14
799.62
-4.13
37.64
-3.38
596.11
-3.33
33.49
-3.03
10000.00
-2.94
133.34
-2.73
153.71
-2.68
30.58
-2.68
10000.00
-2.61
10.45
-2.59
1394.27
-2.58
8.85
-2.54
10.93
-2.30

!

Table 2. Downregulated proteins in the platelet releasates of PIKfyvefl/fl Pf4-Cre
mice.	
  	
  
The numbers of peptide spectral matches to each protein were used for quantitative
comparison between the knockout (KO) and control (Cont) platelet samples. A Bayes
Factor of at least 8 and a fold change of at least 2.0. were used for statistical analysis.
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Further analysis of the sequence coverage and MS spectra of the tryptic peptides
for cathepsin D demonstrated that the releasates of PIKfyve-null platelets contained
predominantly the procathepsin D - the immature and inactive proenzyme form of
cathepsin D – but undetectable levels of mature cathepsin D (Fig. 3.15a-c). To further
validate these findings, we analyzed the expression of cathepsin D in platelet lysates by
immunoblotting. Consistent with the proteomics data, both cathepsin D and procathepsin
D were undedetectable in the lysates of wild-type platelets, and procathepsin D was
highly elevated in PIKfyve-null platelets (Fig. 3.15d). These results suggest that cathepsin
D expression is upregulated in PIKfyve-null platelets, but that the intracellular maturation
of procathepsin D is defective in PIKfyve-null platelets. Consequently, cathepsin D
activity was negligible in both the lysates and releasates of both wild-type and the
PIKfyve-null platelets (Fig. 3.15e). Together, these data demonstrate that PIKfyve
ablation in platelets results in a defective lysosomal pathway reflected by abnormal
storage, maturation, and release of lysosomal enzymes.
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Figure 3.15. PIKfyve-null platelets release increased levels of procathepsin D. (a)
Amino acid sequence of murine cathepsin D. The signal peptide sequence is crossed out
and the propeptide sequence is underlined. The trypic peptides of cathepsin D are
highlighted in yellow. (b) The assigned MS2 spectra of the tryptic peptides contained in
the Cathepsin D propeptide are shown. (c) The peptide TTEPVSELLK spans the
propeptide cleavage site. Note that the predicted N-terminal tryptic peptide of the active
form of cathepsin D (EPVSELLK) was not observed in MS1 nor identified in MS2 with
semi-tryptic enzyme specificity for the database search. (d) Immunoblot of platelet
lysates from control mice and PIKfyvefl/fl Pf4-Cre mice showing the expression of
Procathepsin D. β-actin was used as the loading control (e) Cathepsin D activity of
platelets from control and PIKfyve-null platelets in the absence or presence of protease
inhibitor (n=3 per group).
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Loss of PIKfyve in platelets accelerates arterial thrombosis
Platelets have long been known to contain primary lysosomes and release their
lysosomal enzymes in response to stimuli(Bentfeld-Barker and Bainton 1982, Rendu,
Marche et al. 1987), but the physiologic role of platelet lysosome secretion has not been
clearly delineated. Thus, we tested whether the lysosomal abnormalities observed in
PIKfyve-null platelets correlated with any functional abnormalities. Washed platelets
from control or PIKfyvefl/fl Pf4-cre mice formed aggregates to a similar degree in response
to different agonists (Fig. 3.14b), suggesting that activation of the dominant platelet
integrin, aIIbb3, is intact in the PIKfyve-null platelets. In addition, Akt phosphorylation
was normally induced upon stimulation (Fig. 3.16b), suggesting that the intracellular
signaling pathway in PIKfyve-null platelets is also preserved. To determine the effect of
PIKfyve ablation in platelets during thrombosis in vivo, the carotid arteries of mice were
analyzed for occlusive thrombus formation in response to a chemical injury with ferric
chloride. At 12-16 weeks of age, PIKfyvefl/fl Pf4-Cre mice formed occluding thrombi
significantly faster than their control littermates (3.8 ± 1.6 minutes vs. 6.1 ± 1.2 minutes,
Fig. 3.16a). Since PIKfyve-null platelets showed normal aggregation ex vivo, we
speculated that the excessive secretion of the platelet lysosomal contents from PIKfyvenull platelets could contribute to endothelial damage and systemic inflammation leading
to accelerated thrombus formation. Consistent with this possibility, plasma levels of
vWF, a marker of endothelial damage and systemic inflammation(Lip and Blann 1997),
were significantly elevated in the plasma of PIKfyvefl/fl Pf4-Cre mice when measured by
immunoblotting (Fig. 3.16c) or ELISA (Fig. 3.16d). Together, these results suggest that
excessive lysosomal secretion from PIKfyve-null platelets is associated with endothelial
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damage and systemic inflammation, perhaps underlying excessive thrombosis in
PIKfyvefl/fl Pf4-Cre mice.

Figure 3.16. Loss of PIKfyve in platelets accelerates arterial thrombosis. (a) Time to
occlusion of carotid arteries upon vascular injury with 7.5% of FeCl3 in the control mice
(n=9) and the PIKfyvefl/fl Pf4-Cre mice (n=8). (b) Immunoblot of platelet lysates from
control platelets and PIKfyvefl/fl Pf4-Cre platelets showing the Akt phosphorylation in
resting condition or stimulated with 1U/mL of thrombin for 10 minutes. (c) SDS agarose
electrophoresis showing the multimer pattern of plasma vWF from the control mice (n=3)
and the PIKfyvefl/fl Pf4-Cre (n=3) mice. (d) Plasma levels of vWF from the control mice
(n=3) and the PIKfyvefl/fl Pf4-Cre (n=3) mice were quantified by ELISA. *P<0.05. All
error bars indicate mean ± S.D. Student’s t-test.
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Impaired release of platelet lysosomes reverts the pathology
If the pathological macrophage inflammatory response in PIKfyvefl/fl Pf4-Cre mice
reflects the excessive stimulus-induced secretion of lysosomal enzymes, we hypothesized
that attenuating the release of platelet lysosomes would comparably attenuate the
inflammatory responses. To test this hypothesis, PIKfyvefl/fl Pf4-Cre mice were crossed
with pallid mice, a model of Hermansky-Pudlak Syndrome type 9 (Cullinane, Curry et al.
2011). Pallid mice lack an essential subunit of BLOC-1, a complex required for the
biogenesis of lysosome-related organelles such as pigment cell melanosomes and platelet
dense granules (Marks, Heijnen et al. 2013, Wei and Li 2013). Importantly, stimulusdependent secretion of lysosomal contents is impaired (but not ablated) in platelets from
pallid mice (Novak, Hui et al. 1984). In contrast to PIKfyvefl/fl Pf4-Cre mice that
developed persistent dorsal alopecia and weight gain, PIKfyvefl/fl Pf4-Cre/pallid mice
maintained hair growth until death and exhibited attenuated weight gain (Fig. 3.17a and
3.17b; note that because the pallid mutation also impairs melanosome biogenesis, pallid
mice exhibit hypopigmented fur). As expected, platelet and plasma levels of bhexosaminidase were lower in PIKfyvefl/fl Pf4-Cre/pallid mice than in PIKfyvefl/fl Pf4-Cre
mice (Fig. 3.17c and 3.17d). Together, these data suggest that the release of platelet
lysosomes contributes to the pathogenesis of multiorgan defects in PIKfyvefl/fl Pf4-Cre
mice.
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Figure 3.17. Impaired secretion of platelet lysosomes attenuates the phenotypes of
PIKfyvefl/fl Pf4-Cre mice. (a) General appearance of PIKfyvefl/fl Pf4-Cre mice and
PIKfyvefl/fl Pf4-Cre/pallid mice on C57BL/6 background at 17 weeks of age. In the
presence of the pallid mutation, the hair loss and weight gain are attenuated in the
PIKfyvefl/fl Pf4-Cre/pallid mice. Note that the pallid mice have an underlying defect in
melanosome biogenesis causing hypopigmented fur. (b) Body weight of the PIKfyvefl/fl
Pf4-Cre mice, and the sex-matched and age-matched PIKfyvefl/fl Pf4-Cre/pallid mice. The
average numbers of mice were 5 per time point and per group. The dashed line indicates
the mean ratio of body weight of the control mice. (c,d) Analysis of β-hexosaminidase
activity in the platelet lysate (c) and plasma (d) of the PIKfyvefl/fl Pf4-Cre mice (n=3) and
the PIKfyvefl/fl Pf4-Cre/pallid (n=3) mice. *P<0.05, ** P<0.01. All error bars indicate
mean ± S.D. Student’s t-test.
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CHAPTER 4: SUMMARY, DISCUSSION AND FUTURE DIRECTIONS
4.1) Summary
In this work, we show that PIKfyve kinase activity is critical in limiting the
pathological inflammatory and thrombotic functions of platelet lysosomes. Our data
indicate that PIKfyve kinase activity in platelets is essential for the normal maturation of
cathepsin D and for the proper storage and release of lysosomal enzymes. Unexpectedly,
dysregulated lysosomal homeostasis and enhanced lysosomal release from PIKfyve-null
platelets drive an aberrant inflammatory response in macrophages. This leads to chronic
inflammation and arterial thrombosis that affect the development, body mass, fertility,
and survival of mice.

4.2) Discussion and future studies
PIKfyve regulation of platelet secretome
Our proteomic analysis by mass spectrometry identified 55 proteins that were
differentially expressed in the releasates of PIKfyve-null platelets in comparison to the
releasates of control platelets. These include 17 up-regulated proteins and 38 downregulated proteins. Among all these proteins, 41 proteins (75% of total) have been
previously reported as platelet-released proteins using a mass spectrometry-based
approach (Coppinger, Cagney et al. 2004, Coppinger, O'Connor et al. 2007, HernandezRuiz, Valverde et al. 2007, Maynard, Heijnen et al. 2007, Piersma, Broxterman et al.
2009).
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Among those 17 proteins that were up-regulated in the releasates of PIKfyve-null
platelets, three proteins are lysosomal enzymes (cathepsin D, cathepsin B and maltaseglucoamilase) and two proteins belong to the proteasome subunits (proteasome subunit
alpha type 6 and proteasome subunit beta type 1). Because both the lysosome and the
proteasome are the two main organelles for intracellular degradation, it is tempting to
speculate that in the absence of PIKfyve, a defective lysosomal degradative function may
feedback on the proteasome and activate the proteasomal degradative pathway.
Six of the up-regulated proteins in the releasates of PIKfyve-null platelets are
acute phase reactants including proteins of the complement activation system
(complement c1s subcomponent, complement c1q subcomponent and complement factor
properdin), cholesterol metabolism (apolipoprotein B, phosphatidylcholine-sterol
acyltransferase) and serum amyloid a-1 protein. Although all these proteins have been
previously identified in the platelet releasates, they also belong to the plasma proteins. It
is possible that these acute phase proteins may just reflect an active inflammatory
response by PIKfyve-null platelets. However, we cannot exclude the possibility that some
of these proteins represent plasma contaminants in the platelet releasate samples. Other
proteins that were found also up-regulated in the platelet releasates of PIKfyve-null
platelets include two extracellular matrix proteins normally absent in platelets (collagen
and fibulin1), immunoglobulin light chains, kininogen 2, keratin and inter-alpha-trypsin
inhibitor. However, the significance of the differential expression of these proteins in
PIKfyve-null platelet releasates is currently unknown.
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Cytoskeletal proteins have been consistently reported in the platelet releasates in
the previous studies using a proteomic approach (Coppinger, Cagney et al. 2004,
Hernandez-Ruiz, Valverde et al. 2007, Maynard, Heijnen et al. 2007), which suggest that
they are authentic components of platelet releasates. Among those 38 down-regulated
proteins in the releasates of PIKfyve-null platelets, 14 proteins are cytoskeletal proteins
(tropomyosin, myosin light polypeptide 6, zyxin, filamin A, myosin regulatory light
polypeptide 9, alpha-actinin 1, vinculin, talin 1, tubulin beta 4B chain, WD repeatcontaining protein 1, tubulin alpha 1B chain, myosin 9, tubulin beta 1 chain and cofilin1).
Interestingly, our immunoblotting analysis of platelet lysates for actin, tubulin and
vinculin demonstrated no differences between the WT and PIKfyve-null platelets, which
suggests that the total amount of cytoskeletal proteins is likely intact in PIKfyve-null
platelets. The significance of a potential decrease of cytoskeletal proteins in the releasates
of PIKfyve-null platelets remains to be explored.
Other proteins that are expressed lower in the PIKfyve-null platelet releasates
include 13 proteins that have been previously detected in the releasates of platelet alpha
granules or dense granules (Hernandez-Ruiz, Valverde et al. 2007, Maynard, Heijnen et
al. 2007). These proteins include factor XIII A chain, beta parvin, protein disulfideisomerase A3, vWF, latent-transforming growth factor beta binding protein, 14-3-3
protein eta, multimerin-1, transforming growth factor beta 1, heat shock cognate 71kDa
protein, glia-derived nexin, 78kDa glucose-regulated protein, coagulation factor V,
metalloproteinase inhibitor 3 and 14-3-3 protein zeta/delta. To validate these findings, we
performed immunoblotting analysis of vWF and PF4 in the lysates from WT and
PIKfyve-null platelets. Interestingly, similar to the cytoskeletal proteins, the expression of
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vWF and PF4 was similar in the lysates from the WT and PIKfyve-null platelets. In
addition, the secretion of P-selectin and ADP were also normal in thrombin-stimulated
PIKfyve-null platelets, which suggests that the efficiency of exocytosis of alpha granules
and dense granules are intact in PIKfyve-null platelets. Therefore, although our proteomic
analysis provided a comprehensive list of potential candidate proteins that could be
differentially expressed in the PIKfyve-null platelet releasates, it is essential that these
findings need to be validated by a separate experimental approach before we draw any
final conclusion.
Label-free mass spectrometry-based quantitative proteomics is a powerful
technology for the analysis of protein abundance between samples. However, there still
exist several limitations. 1) The use of spectral counts as a method of quantification only
provides relative abundance of proteins in samples. In our study, the spectral counts were
used to compare the abundance of a specific protein in the WT vs. PIKfyve-null platelet
samples, but not for the analysis of relative abundance across different proteins. 2) The
presence of highly abundant proteins may reduce the detection sensitivity of lower
abundant proteins or peptides. This limitation may explain why the β-hexosaminidase
level was found to be higher in the PIKfyve-null platelets using a chromogenic activity
assay but not by mass spectrometry analysis. 3) Because mass spectrometry analysis is
based on protein digests or peptides, information on the intact protein cannot be directly
provided.
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The role of PIKfyve in the maturation of lysosomal enzymes.
We show that the precursor lysosomal protease, procathepsin D, is excessively
stored and released in PIKfyve-null platelets, which suggests that PIKfyve is essential in
the maturation of procathepsin D to active cathepsin D. In normal physiological
conditions, cathepsin D is synthesized as a pre-pro-enzyme in the endoplasmic reticulum.
After removal of signal peptide, pre-pro-cathepsin D yields procathepsin D, which is
modified by N-linked glycosylation and transported to Golgi. In Golgi, procathepsin D is
further modified by the addition of mannose-6-phosphate residues (M6P), which bind to
the mannose-6-phosphate receptors (M6PR) in the TGN for its delivery to endosomes. In
the acidic endolysosomal compartments, procathepsin D is further processed by
proteolytic cleavage to active cathepsin D (Kornfeld 1987). The M6PR must then recycle
to the TGN for another round of transport. Therefore, procathepsin D maturation depends
on the proper trafficking of procathepsin D from the TGN to endosomes for its
proteolytic activation in acidic compartments. Hence, the defective maturation and
accumulation of procathepsin D in PIKfyve-null platelets suggest that PIKfyve is critical
for procathepsin D trafficking from the TGN to endosomes. This conclusion is consistent
with a published study showing that PtdIns(3,5)P2 deficiency leads to the defective
retrograde trafficking of M6PR from endosomes to the TGN (Rutherford, Traer et al.
2006), which would ultimately exhaust the M6PR from the TGN and result in a defective
maturation and default secretion of procathepsin D. Similarly, the fibroblasts of Vac14null mice develop defective steady-state localization of M6PR, and they also accumulate
the immature forms of cathepsin D (Zhang, Zolov et al. 2007). Together, these studies
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suggest that the PIKfyve synthesis of PtdIns(3,5)P2 regulates the trafficking from the
TGN to the lysosome, essential for the maturation of procathepsin D.
However, the proteolytic maturation of procathepsin D also needs low pH in the
lysosome. Consequently, a defective lysosomal acidification may also impair the
proteolytic maturation of procathepsin D. In yeasts, PIKfyve is required for acidification
of the lysosome-like vacuole (McCartney, Zhang et al. 2014). However, chemical
inhibition and siRNA knockdown of PIKfyve in mammalian cells do not impair the low
pH of endolysosomal comparments (Kim, Dayam et al. 2014). These studies suggest that
PIKfyve might have a different role in the regulation of lysosomal pH in yeasts and
mammalian cells. In future studies, it would be important to verify the lysosomal
acidification as well as cellular functions that depend on the proper lysosomal
acidification in PIKfyve-null mammalian cells.

The role of PIKfyve in the expression of lysosomal proteins
We also show that PIKfyve-null platelets have increased expression of lysosomal
proteins, which include lysosomal membrane proteins such as LAMP-1 as well as
lysosomal enzymes such as β-hexosaminidase and procathepsin D. These findings
suggest that PtdIns(3,5)P2 deficiency might additionally feedback on lysosomal protein
biosynthesis.
The gene network of lysosomal biogenesis and functions is tightly regulated by
the master regulator transcription factor EB (TFEB) (Sardiello, Palmieri et al. 2009,
Settembre, Fraldi et al. 2013). In basal conditions, TFEB is phosphorylated and localized
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in the cytoplasm. However, in response to lysosomal dysfunction or starvation, TFEB is
dephosphorylated and rapidly translocated into the nucleus. Phosphorylation of TFEB has
been shown to be regulated by different kinases including mTORC1, ERK2 and PKCβ
(Settembre, Fraldi et al. 2013). Interestingly, PIKfyve synthesis of PtdIns(3,5)P2 has been
shown to be critical for the recruitment of mTORC1 to the plasma membrane and its
activation in adipocytes (Bridges, Ma et al. 2012). In yeast, PtdIns(3,5)P2 recruits
TORC1 to the lysosome-like vacuole and induces multiple TORC1-dependent pathways
(Jin, Mao et al. 2014). However, whether PIKfyve synthesis of PtdIns(3,5)P2 and its
activation of mTORC1 is necessary for the phosphorylation of TFEB to keep it inactive
in the cytosol remains unknown. In our preliminary study, we found that PIKfyvedeficient cells have increased dephosphorylated forms of TFEB in their cell lysates (data
not shown), which suggests that PIKfyve is required for the phosphorylation of TFEB. In
future studies, one could test the hypothesis that PIKfyve deficiency impairs the
activation of mTORC1 pathway and therefore the phosphorylation of TFEB, which
results in the nuclear translocation of TFEB and activation of the lysosomal gene
network. This hypothesis could be tested by comparing in the control and PIKfyve-null
cells : 1) the activation of mTORC1 pathway by immunoblotting analysis, 2) the cellular
localization of TFEB (cytosolic vs. nuclear) by immunofluorescence microscopy
analysis, and 3) the expression of lysosomal genes by microarray analysis or quantitative
RT-PCR. The impaired activation of mTORC1, nuclear translocation of TFEB, and
increased transcripts of lysosomal genes in PIKfyve-null cells could explain the increased
expression of lysosomal proteins in these cells.
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The role of PIKfyve in the regulation of lysosomal functions
Although our study on the maturation of lysosomal enzymes was limited to
procathepsin D in PIKfyve-null platelets, a defective protein trafficking from the TGN to
endosomes could potentially impair the processing and functions of many lysosomal
proteins and interfere with normal lysosomal functions. Most mammalian cells have
lysosomes and their functions are mainly intracellular. For example, within the cell,
lysosomes are critical for the degradation and recycling of extracellular materials,
autophagy, nutrient sensing, and control of energy metabolism (Settembre, Fraldi et al.
2013). However, lysosomes can be exocytosed by professional secretory cells in
physiological processes and the released lysosomal contents play essential roles at the
extracellular space. These professional secretory cells include cytotoxic T lymphocytes
that release granzyme and perforin for cytotoxicity, osteoclasts that release proteases for
bone resorption, melanocytes that release and transfer melanin to keratinocytes for
pigmentation, and platelets. However, the physiological role of the platelet secretion of
lysosomes is poorly understood.
Megakaryocytes and platelets possess lysosomes that contain different hydrolases
including proteases and glycosidases, which are released upon platelet activation
(Bentfeld and Bainton 1975, Bentfeld-Barker and Bainton 1982) (Ciferri, Emiliani et al.
2000). It has been speculated that the release of platelet lysosomal enzymes may be
required for the remodeling of extracellular matrix during wound healing (Rendu and
Brohard-Bohn 2001). In addition, the pathological release of lysosomal enzymes may
also cause the local injury of the vascular wall leading to atherosclerosis and the focal
thickening of arteries (Muir and Bowyer 1984). Thus, proper regulation of the platelet
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lysosomal secretion would be essential to maintain a normal response to wound healing,
and also to avoid the inflammatory and thrombotic defects that could result from the
excessive platelet lysosomal secretion. Consistent with this concept, this study shows that
the excessive storage and secretion of lysosomal enzymes from platelets lacking PIKfyve
result in the accelerated arterial thrombosis and inflammation observed in PIKfyvefl/fl Pf4Cre mice. Thus, our studies further support that an aberrant release of platelet lysosomal
contents could be pathogenic and that the lysosomal homeostasis in platelets play a
crucial role in limiting the proinflammatory and prothrombotic functions of platelets.

PtdIns(3,5)P2 deficiency is reminiscent of lysosomal storage disorders
Similar to PIKfyve-null platelets, excessive release of the lysosomal enzymes are
also seen in the lysosomal storage disorders, Mucolipidosis II and Mucolipidosis III
(Platt, Boland et al. 2012). In these diseases, an inability to generate the M6P recognition
signal on the lysosomal enzymes impairs their delivery from the TGN to the lysosome via
the M6PR pathway resulting in the excessive release of lysosomal enzymes
extracellularly (Vogel, Payne et al. 2009).
Like PIKfyve deficiency, the deficiency of the inositol phosphatase and PIKfyve
chaperone protein called Fig4 results in the reduced intracellular PtdIns(3,5)P2
concentrations. Notably, Fig4-deficient mice develop enlarged endolysosomal vacuoles
and excessive accumulation of lysosomal proteins, reminiscent of lysosomal storage
diseases (Zhang, Chow et al. 2008).
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Likewise, mice lacking another PIKfyve-binding partner called Vac14 have
decreased synthesis of PtdIns(3,5)P2 and develop excessive vacuolation of late
endosomal and lysosomal compartments(Zhang, Zolov et al. 2007). Together with our
findings, these studies further support that the depletion of PtdIns(3,5)P2 by impairing
any components of the PIKfyve complex could lead to the features that are reminiscent of
those found in lysosomal storage disorders.

PIKfyve deficiency induces secondary pathologies in other cells
It is notable that lysosomal storage diseases are frequently associated with
inappropriate immune responses that result in chronic inflammation. For example, tissue
infiltration of reactive macrophages can lead to visceral organomegaly in both Gaucher
and Niemann-Pick diseases (Boven, van Meurs et al. 2004, Vitner, Platt et al. 2010).
Likewise, microglial activation is frequently associated with the neuropathology in
Mucopolysaccaridoses (Parkinson-Lawrence, Shandala et al. 2010).
Similar to these findings, we unexpectedly observed that the ablation of PIKfyve
in platelets causes inflammatory responses that are associated with robust macrophage
defects, which lead to multiorgan failure in mice. Using several lines of evidence, we
demonstrated that this macrophage phenotype is non-cell-autonomous, showing that
PIKfyve-null platelets can induce aberrant responses in normal macrophages. We further
demonstrate that impairing the lysosomal secretion from platelets significantly attenuates
the macrophage pathology leading to multiorgan abnormalities in PIKfyvefl/fl Pf4-Cre
mice, which suggests that platelet release of lysosomes contribute to the macrophage
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pathology. However, the exact mechanism by which the lysosomal contents of PIKfyvenull platelets induce the macrophage pathology remains unknown. Further studies are
required to identify what components of platelet lysosomes contribute to the macrophage
pathology. A strong candidate protein is the procathepsin D, which is the lysosomal
protein with the highest relative abundance in the releasates of PIKfyve-null platelets in
comparison to control platelets. One could test whether the releasates from PIKfyve-null
platelets can directly contribute to the vacuolation and/or proliferation of macrophages by
culturing WT macrophages in the presence of either the control or PIKfyve-null platelet
releasates, and observing the morphological changes and cell proliferation by live cell
imaging and biochemical assays. Similarly, WT macrophages could be treated either in
the presence or in the absence of a recombinant procathepsin D, and examined for
changes in their cell morphology or proliferation.
Once a specific PIKfyve-null platelet lysosomal proteins causing the macrophage
pathology is identified, further studies will be necessary to determine how this protein
induces cytoplasmic vacuolation and cell proliferation in macrophages. Similar to
PIKfyve-null platelets, several cancer cells overexpress and hypersecrete procathepsin D.
In some conditions, procathepsin D has a paracrine function in the tumor environment by
increasing fibroblast outgrowth and tumor metastasis. One proposed model is that
procathepsin D could function as a signaling molecule that activates MAPK signaling
pathway and regulate cellular apoptosis and proliferation in cancer cells (Vetvicka,
Vashishta et al. 2010). Thus, it would be intriguing to investigate whether the addition of
PIKfyve-null platelet releasates could activate MAPK signaling pathway in WT
macrophages. It has been also shown that the secreted procathepsin D by cancer cells can
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be endocytosed by other cells in the tumor microenvironment and change the degradative
functions of the lysosomes in the recipient cells. In future studies, it would be interesting
to study whether the procathepsin D released by PIKfyve-null platelets could be
endocytosed by WT macrophages and impair the lysosomal degradative functions leading
to lysosomal vacuolation in macrophages.
Interestingly, this inflammatory response has not been described in mice lacking
Fig4 or Vac14. This could be explained because these mice do not survive long enough to
fully develop the robust tissue accumulation of macrophages seen in PIKfyvefl/fl Pf4-Cre
mice. However, a similar non-cell-autonomous phenomenon has also been observed in
Fig4-null mice, which have a neurodegenerative disorder (Chow, Zhang et al. 2007). The
genetic restoration of Fig4 exclusively in the neuronal cells of Fig4-null mice not only
reverts the dysfunctions of neuronal cells, but it also reverts the dysfunctions of the
adjacent oligodendrocytes including hypomyelination and maturation defects (Winters,
Ferguson et al. 2011). Together with our findings, these studies indicate that the depletion
of PtdIns(3,5)P2 in a single cell type may have indirect implications in other cell types.
Furthermore, they also show that our findings are consistent with the broad secondary
defects shown in lysosomal storage disorders.

4.3) Conclusion
Our study demonstrates the novel finding that PIKfyve kinase activity is a critical
regulator of the lysosomal pathway in mouse platelets. This work also provides evidence
that in addition to the effects mediated by the release of platelets alpha and dense
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granules, secretion of platelet lysosomes may be a previously unrecognized initiator of
vascular damage and inflammatory responses. These findings could have important
implications and applications in the diagnosis and in the design of novel targets for
clinical disorders mediated by platelets.
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